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         Matrix Metalloproteases (MMP) inhibition is currently brought to the focus of 
medicinal chemistry research due to their essential roles in many human diseases. To 
elucidate the functions of each individual MMP, it is imperative to synthesise small 
molecule/probes which can selectively target a particular MMP instead of those which 
exhibit broad spectrum inhibition against the whole family.  In this project, we aim at 
profiling MMPs substrate specificities in a high-throughput manner using small molecule 
microarrays as well as elucidating their biological functions through activity-based 
protein labeling. Herein we introduce synthetic routes toward different P1’ substituted 
MMPI warheads and their use in the MMPI library synthesis on solid phase. In addition,  
by taking the advantages of the relative ease and convenience of “Click Chemistry” in 
constructing focused chemical libraries, we have been able to apply this strategy to 
synthesise a 96-membered library of metalloprotease inhibitors followed by in situ 
screening. Moreover by using the same strategy, we successfully demonstrate that the 
facile synthesis of various affinity-based hydroxamate probes that enables the generation 
of activity-based fingerprints of a variety of metalloproteases, including matrix 















         Metalloproteases, together with serine, cysteine and aspartic proteases, represent the 
four major classes of proteolytic enzymes which mediate the hydrolysis of the amide 
bond. These proteases have been found to be involved in a variety of cell functions such 
as DNA replication, cell-cycle progression, cell proliferation, differentiation, migration. 
Deregulations of protease activities are known to cause many diseases such as cancer, 
HIV, malaria, Alzheimer’s diseases. Overall proteases represent 5-10% of the potential 
drug targets. 1
         Matrix metalloproteinases (MMPs) belong to a family of homologous zinc 
endopeptidases that are capable of hydrolyzing all known constituents of the extracellular 
matrix (ECM).2 There are currently at least 23 members of human MMPs that have been 
identified so far. All MMPs are expressed as proMMPs which are activated by proteolytic 
cleavage between the pro and catalytic domains or chemical modification of the cysteine 
side chain followed by dissociation of the pro domain. 3 MMPs are characterized by a 
highly conserved zinc binding sequence HEXXHXXGXXH (X is any amino acid) at the 
active site followed by a conserved methionine residue located beneath the active site 
zinc. The catalytic zinc ion is coordinated to three histidine residues and is responsible 
for the activation of the water molecule at the active side. The pKa of the water molecule 
is lowered by coordination to the zinc ion and hydrogen bonding to the glutamic acid 
residue at the catalytic site and is thus activated towards nucleophilic attack of the 
electron-deficient carbon centre of the scissile peptide bond. As shown in Figure 1, 
during the hydrolysis, the zinc ion stabilizes the negative charge formed in the tetrahedral 
1 
intermediate, while the Glu and Ala residues aid in the proton transfer from the water 
molecule to the nitrogen atom, making it a good leaving group. The ammonium group 




Figure 1 Catalytic mechanism of MMPs 
 
          Despite their well-documented pro-tumorigenic actions, only three MMPs - MMP-
1, 2 and 7 - have been experimentally validated as potential cancer targets. Another three 
(MMP-3, 8 and 9) have recently been classified as antitargets due to the key role they 
play in normal tissue homeostasis. With the precise biological functions of other human 
MMPs remaining largely unknown, the development of novel chemical and biological 




1.2  Matrix Metalloprotease inhibition 
 
           Two general methods have been applied to the identification of matrix 
metalloprotease inhibitors: one method is the substrate-based design of pseudopeptide 
2 
derivatives; another approach is the random screening of nature compound libraries as 
well as synthetic small molecule libraries.5 However such random screening of large 
libraries yields minimal results, with few compounds found to be potent and selective 
MMP inhibitors.6 Thus most of the research efforts are still devoted to the design of 
peptide based inhibitors. The simplest form of an effective MMP inhibitor is a zinc-
binding group (ZBG) conjugated with a peptide sequence which mimics the natural 
substrate of MMPs. 7  Based on the selection of the ZBG; the corresponding peptide 
sequence could be positioned either on the left-hand side (LHS) or the right-hand side 
(RHS), or on both sides of the cleavage site. Among all the ZBGs developed so far, the 
hydroxamic acid has been found to be one of the most potent warheads against MMPs. 8  
It is noted while some novel heterocyclic zinc-binding groups which are more potent and 
selective than acetohydroxamic acid (AHA) have been reported by Cohen et al, 9 no full 
inhibitor based on the those ZBGs has been synthesized so far. The design and 
development of inhibitors employing these promising ZBGs could potentially be another 
interesting research project. 
           With the hydroxamic acid as the ZBG, inhibitors that are designed to target the 
enzyme subpockets on the right hand side of the active side exhibit particularly potent 
inhibition. The standard nomenclature used to designate substrate / inhibitor residues that 
bind to corresponding enzyme subsites is adopted here 10 as shown in Figure 2.  
  
3 
Figure 2 Standard nomenclature for substrate residues and their corresponding binding 
 
 
        Another factor critical to achieving potent inhibition is the length between the 
carbon bearing P1’ substitution and the hydroxamic acid. It was shown by Johnson and 
co-workers that succinyl hydroxamic acid derivatives are more potent inhibitors of 
MMP-1 than either the corresponding malonyl or glutaryl derivatives. 11 For other ZBGs 
like the thiol, formylhydroxylamine, and phosphonate groups, the insertion of a single 
methylene spacer between the ZBG and the carbon bearing the P1’ substituent also 
resulted an improvement in activity. Thus peptide-based succinyl hydroxamates has 
became one of the most widely exploited scaffolds of MMP inhibitors. Inhibitors 
containing the hydroxamate ZBG typically exhibit broad-spectrum inhibition towards 
most metalloproteases, rather than exclusively towards MMPs. As shown in the 
following Figure 3, the P1’ position had the greatest interaction with the S1’ subpocket of 
































Figure 3 Binding of a hydroxamate inhibitor to MMP-7 
 
           The greatest challenge in constructing MMP inhibitors is achieving selectivity -
targeting specifically one particular member of MMP while having little or no effect on 
4 
other MMP members. This is of particular importance, especially considering the fact 
that some MMPs play essential roles in the normal cellular function and are defined as 
anti-targets, inhibition of which will counterbalance the benefits of target inhibition.2a 
Selective inhibition could be achieved by simultaneously targeting multiple different 
MMP binding pockets. Among all the substrate binding pockets of MMPs, the S1’ pocket 
has been identified as the major determinant of substrate specificity. According to the 
structural studies utilizing X-ray crystallography, NMR and computer modeling 
techniques, the MMPs can be divided into two structural classes depending on the depth 
of the S1' pocket. 13  This selectivity pocket is relatively deep for the majority of the 
enzymes like gelatinase A (MMP-2), stomelysin-1 (MMP-3) or collagenase-3 (MMP-13), 
but in the case of human fibroblast collagenase (MMP-1) or matrilysin (MMP-7) it is 
partially or completely occluded due to an increase in size of the side-chain of amino acid 
residues that form the pocket. As a result, selective inhibition of the deep pocket enzymes 
over the short pocket enzymes is easy to achieve by incorporating of an extended P1' 
group in MMP inhibitors, whereas the presence of smaller P1' groups generally leads to 
broad-spectrum inhibition. However, it has also been found that the S1’ pocket can 
undergo conformational changes in order to accommodate substrates or inhibitors that 
can form favorable interactions with the amino acid residues in the S1’ pocket. 14  
         
        One aim of our project is to achieve both potent and selective inhibition aganist 
MMPs. Our design focused on the co-operative effects across P1’, P2’ and P3’ positions 
that contributes to overall inhibition potency and selectivity. Moreover, biotin tag was 
5 
incorporated into the inhibitor design as a latent tag which could be applied to the future 















































Figure 4 Structure of the 1400 MMP inhibitors 
 
1.3  Fragment-based discovery of metalloprotease inhibitors 
 
          Fragment-based drug discovery has recently been brought to the attention of 
current research in medicinal chemistry, enabling us to profile the N2 possibilities with 
N+N combinations. 15 Compared to traditional high throughput screening and structure 
based drug design, fragment-based drug discovery offers two unique advantages: First, a 
library of small fragments represents a much higher proportion of the available ‘chemical 
space’ for low molecular weight compounds than a large library of drug-sized molecules 
does for higher molecular weight compounds, because the number of possible molecules 
6 
rises exponentially as molecular weight increases; Secondly, it decreases the synthetic 
effort, since only the selected fragments need to be assembled and tested with the target 
protein(s). 16  Fragment-based drug discovery typically involves a two-step process:  
optimal fragments are first identified by means of functional or direct binding assays at 
high concentrations, or by other techniques such as NMR-Based Screening, Mass-
Spectrometry-based methods and Crystallography-based approaches etc. This is followed 
by linking the individual fragments using chemoselective ligation reactions like sulfur-
disulfide exchange reaction, 17 oximine formation, 18amide bond reaction 19 as well as 
click chemistry. 20  In additional to this traditional process of fragment based drug 
discovery, there is an emerging research direction in this field which relies on the enzyme 
as the template to assemble its own inhibitors.21 This is in a way similar to dynamic 
combinatorial chemistry, with the ligation reaction occurring only between the building 
blocks that are amplified in the presence of enzymes template in which they occupy.  
 
        Fragment-based drug discovery not only allows us to identify enzyme inhibitors 
with novel structures, it also offers us a straightforward way of modifying existing lead 
drugs. We previously constructed a 400-member MMPI library and identified a potent 
inhibitor against thermolysin with IC50 =9.9 nM and Ki = 2.4 nM inhibition. 22 However, 
despite its promising results in vitro, peptide-based compounds have no in vivo activity 
due to rapid degradation by endogenous proteases. In developing non-peptide based small 
molecule inhibitors, fragment-based synthesis offers a convenient way to modify existing 
peptide-based inhibitors to construct inhibitors with non-amide bond linking two different 
components of the inhibitor. By simply splitting the model compound into two fragments, 
7 
each targeting a different binding pocket of the enzyme, we can easily generate a library 
of analogues for each fragment, with a reactive group appropriate for the ligation reaction 
appended to each fragment. Herein, we successfully applied this strategy employing the 
[1,3] dipolar cycloaddition of alkynes and azides as the ligation reaction for the rapid 
































Figure 5 “Click” Synthesis of Matrix Metalloprotease (MMP) inhibitors 
 
 
1.4  Inhibitor Fingerprinting 
 
           In the post genomic era, research efforts have been shifted from enzyme 
identification to enzyme catalytic activity characterization.23  The latter is important as it 
reveals not only the catalytic mechanism of the enzyme, but also generates a unique 
pattern of “inhibitor fingerprinting” against a known set of inhibitors. 24  In contrast to 
the traditional small molecule microarray (SMM) screening methods which simply rely 
on non-covalent ligand-protein interactions, “inhibitor fingerprinting” generates a unique 
inhibition pattern based specifically on the catalytic activity of the enzyme, thus 
eliminating false positives which result from inconsequential affinity between the ligand 
and non-targeted regions of the protein. The first “inhibitor fingerprinting” experiment 
was demonstrated by Diamond and Gosalia who developed a novel nanoliter-scale 
screening assay by utilizing nanoliter droplets as microreactors for testing small molecule 
8 
inhibitors against three different human caspases. A total of 352 small molecule 
inhibitors were printed as individual spots of glycerol on a glass slide. Subsequently an 
aerosolized mixture of caspase and a fluorogenic substrate were applied to assemble 
multi-component reactions at each reaction center. 25 The strength of the fluorescence 
signal generated reciprocally correlates with inhibitor potency. This strategy revealed a 
caspase inhibitor that showed high potency against all three of the caspase isoforms 
screened. However, the use of the viscous mediums such as glycerol and DMSO limits 
general applicability of this strategy in scenarios requiring predominantly aqueous 
environments. We have developed an alternative “nanodroplet” method for screening of 
inhibitors. In our earlier work, 37 enzymes belonging in different classes were spotted in 
spatially addressable, segregated droplets on a glass slide coated with suitable fluorogenic 
substrates (either small molecule- or protein-based). Upon incubation, nanodroplets 
containing active enzymes showed up on the microarray as discrete fluorescent spots 
whose intensities directly correlated with the relative activity of the spotted enzymes. 26 
The feasibility of our strategy for high-throughput identification of enzyme inhibitors was 
demonstrated by screening a 400 member peptide-based small molecule library against 
thermolysin. Each member of the library had a hydroxamic acid “warhead” and an 
invariant isobutyl moiety at the P1’ position while diversity was generated by substituting 
P2’ and P3’ positions with combinations of all the 20 natural amino acids.22   By printing 
pre-incubated nanodroplets of enzyme-inhibitor mixes onto a protease-sensitive glass 
surface, we obtained the inhibitor fingerprint profiles for thermolysin in the terms of 
fluorescence intensity of the spots. Overall this strategy offers not only a rapid method 
9 
for inhibitor profiling and discovery, but also a viable method for the chemical screening 
of huge combinatorial libraries against virtually any enzyme class.  
 
1.5  Activity-based metalloprotease profiling 
 
           With the completion of human genome project, there is an urgent need to identify, 
characterize and assign biological functions of all proteins expressed by the genome, 27 
because it is the expressed proteins, not the genome, which are eventually responsible for 
the different biological functions inside the cell, like cell signaling, differentiation, 
proliferation and translocation. 28  However the traditional methods of high throughput 
proteome profiling like two-dimensional gel electrophoresis (2D-GE) only allow us to 
detect the abundance of the protein, while revealing no information of the activity of the 
protein. 29 The activity-based proteome profiling approach which was initially developed 
by Cravett et al 30 uses active site-directed, small molecule probes that chemically react 
with certain classes of enzymes in a complex proteome, and can therefore report unique 
profiles of enzymes on the basis of their catalytic activities. The probe normally consists 
of two components: the reactive “warhead” which is responsible for the selective 
covalent modifying the active site of a particular enzyme family based on the unique 
enzyme catalytic mechanism; a reporter group like a fluorescence or biotin tag that is also 
necessary for the facile detection or purification purpose.29b Presently, this strategy has 
been successfully applied to profile all the four major classes of protease, such as 
aspartic,31a serine, 30 cysteine proteases 32b, 32c and metalloproteases.32d, 32e It is necessary 
to mention that in the case of profiling enzymes whose hydrolytic mechanism does not 
involve any covalent intermediates, such as metalloproteases, the affinity-based strategy 
is applied. For affinity based protein profiling as shown in Figure 6, the reactive 
10 
“warhead” delivers the probe to the target protein and forms only non-covalent 
interaction with the active site. Immobilization of the probe to the protein results from 
UV irradiation, activating the photo-labile group and forming a highly reactive radical 
which reacts with the protein to form a robust covalent bond. In addition to these two 
units, a reporter group (fluorescence or biotin tag) is also necessary. Our group has 
pioneered in this field by introducing and demonstrating this strategy for the profiling of 
metalloproteases and aspartic proteases. 32a, 32f  Herein, we expand the same strategy by 
taking a step further in the aim of designing specific metalloprotease inhibitors which 
selectively target a particular metalloprotease in the presence of other family members, in 
contrast to the previous probes which only discriminates between different enzyme 
families. The selectivity was primarily achieved by introducing different P1’ substitutions 
in the warhead, as this substitution is the major determinant of selectivity and activity of 
right-hand based matrix metalloprotease inhibitors. Our probe design takes advantage of 
the click chemistry reaction to quickly assemble the two fragments together.  
 
 
Figure 6 Labeling mechanism of activity-based MMP probes. Abbreviations: WH = 
warhead; BP = benzophenone; UV = ultraviolet; TER = tetraethylrhodamine.  
 
 
         Comprehensive knowledge of the location of proteins within cellular 
microenvironments is critical for understanding their functions and interactions. Ideally, 
localization information indicates not only where a protein is found, but also temporal 
and spatial movements. 32  Our project aims at visualization of a particular matrix 
11 
metalloprotease within specific organelles. The results from this study will help us better 
understanding the relationship between the disease stages and the proteolytic activity of 
matrix metalloproteases. Specific targeting of affinity-based MMP probes to a pre-
defined organelle could be achieved by highly orthogonal binding pairs, such as the 
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Chapter 2 Developing Solid Phase Synthesis Strategy of Succinyl 
Hydroxamate-based Matrix Metalloprotease Inhibitors (MMPIs) 
 
2.1 Design of synthesis route of warheads bearing hydrophobic P1’ substitutions 
      Although several MMPIs have successfully entered phase III clinical trials, the 
results have turned out to be disappointing. 34 There are still no MMPIs approved for 
cancer treatment so far. While it is debatable that the reason for the clinical failure of 
MMPs is due to their broad-based, non-specific inhibitory activity across the MMP 
family, the fundamental issue is that the specific role that each individual MMP in 
maintaining normal cellular function has not been properly elucidated. Defining these 
roles clearly will be necessary to identify potential treatment strategies. To address this 
problem, what is needed is the selective inhibition or labeling of only one particular 
MMP, while leaving other MMPs unaffected. It is thus desirable to develop highly 
efficient synthetic and screening strategies that allow rapid generation and screening of 
small molecule inhibitors/probes possessing not only high potency but more importantly 
good selectivity towards MMPs.  
 
    All previous succinyl hydroxamate based MMPIs have been synthesized in solution 
phase via multiple transformations. 35 However in order to develop a facile synthesis 
method which allows us to generate large small molecule libraries mimicking MMP’s 
natural substrate, we have to rely on solid phase synthesis,  as it is one of the cheapest 
13 
and most convenient way to construct libraries. 36 We have been able to design and 
synthesize trityl protected MMPI warheads with the structure CPh3ONH-Suc(2-P1’)-
COOH, which  were shown to be compatible with standard Fmoc peptide chemistry/TFA 
cleavage procedures (Figure 8). Our warhead design was based on known molecular 
templates of Marimastat, Batimastat, and GM6001, three broad-spectrum hydroxamate 
inhibitors of matrix metalloproteases (Figure 9). It is noted that Overkleeft and 
coworkers independently reported a similar method based on the synthesis of N-Boc-O-














































Marimastat Batimastat GM6001  
 
Figure 9 Three broad-spectrum potent MMP inhibitors in clinical trials 
 
 
2.2 Design synthesis route of warheads with P1’ substitution mimicking nature 
amino acid side chains 
 
        Five major interactions have been involved in the formation of protein 3-D structure, 
namely hydrogen bonding, hydrophobic interaction, π-π interaction, electrostatic 
14 
interaction and Van der Waals interaction. It is useful to design an inhibitor which can 
selectively form electro-static interaction with the target protein, which is the strongest 
interaction among them, thus simultaneously achieving both selectivity and potency.38
      Our previously developed solution phase synthesis route of MMPI warheads only 
allows us to synthesis those warheads which bear hydrophobic side chains (6A-6H). A 
new synthetic strategy is needed to synthesis succinyl hydroxamate warheads which 
contain all natural amino acid side chains, if possible. This is reasonable as MMPs 
specifically and efficiently hydrolyses the endogenous substrate with natural amino acid 
side chain in the P1’ position. In order to mimic the strong binding interactions between 
MMP and its natural substrate, we aimed to expand our warhead library size to include 
those containing acidic, basic and hydrophilic side chains. In this project,  four 
hydroxamates (6I-6L) introduces side chains possessing acidic and basic groups, as well 
as hydrophilic groups of hydrogen-bonding property, at the P1’ position, thus are 
synthesized and expected to be able to form favorable electrostatic interactions with 
different S1’ binding pockets of MMPs. The acid-labile protecting groups in 6I-6K were 
chosen such that the warheads are compatible with standard solid-phase Fmoc chemistry, 
allowing them to be used in future for large-scale synthesis of probe libraries. Detailed 
synthesis of the above four warheads will be described in the experimental section. There 
are several considerations in designing the synthesis route: it should be general, enabling 
the facile incorporation of a wide variety of P1’ side chains and, when necessary, precise 
stereospecific control can be exerted over the chiral center located in the warhead (except 
6L). The synthesis was accomplished by standard enolate chemistry coupled with Evan’s 
oxazolidinone auxillary, with different side chains being introduced from their 
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corresponding alkyl bromides (except sulfone warhead). The hydroxamate was protected 
with a trityl group, ensuring its compatibility with standard Fmoc peptide chemistry/TFA 
































6I 6J 6K 6L  
 
Figure 10 Structures of 4 MMPI warheads which bear functional groups 
 
 
2.3 Spilt and pool synthesis of small molecule library using IRORI  
 
          We first synthesized a 400-member small molecule library with the scaffold 
HONH-Suc(2-iBu)–P2’–P3’–Gly–Gly–Lys(biotin)–CONH2, as shown in Figure 11. Each 
inhibitor in the library comprises a succinic hydroxamate ‘‘warhead’’ (a highly potent 
zinc-binding group against metalloproteases), in which the P1’ residue was maintained as 
an isobutyl group throughout. The design was based on the structures of Marimastat, 
Batimastat, and GM6001, three broad-spectrum potent hydroxamate inhibitors of MMPs 
(Figure 2.1.2). With variations across P2’ and P3’ positions in the library, we aimed to 
profile both the potency and selectivity of individual members against different 
metalloproteases, in particular MMPs. A flexible linker and biotin were incorporated into 
each inhibitor for future proteomic applications. The construction of 400 members MMP 
inhibitors library was achieved by using standard Fmoc solid phase peptide synthesis, 
IRORI split and pool directed sorting technology (Scheme 2.3).39  Final product was 
released from the solid phase by standard TFA cleavage protocol. The average 
16 
concentration of individual inhibitors in DMSO stock solution was measured to around 




























Figure 11 Structure of 400-member hydroxamate inhibitors. Diversity was generated at 
P2’ and P3’ positions with 20 natural amino acids. 
 
 
         Following the same synthesis protocol, we next expanded the library size to 1000 
member by incorporating 10 different warheads (6A, 6C, 6D, 6E, 6F, 6G, 6I, 6J, 6K, 6L) 
in the P1’ position and 10 variations across P2’ and P3’ positions. A minor change has 
been made in the last step solid phase coupling reaction: instead of using 
HOBt/HBTU/DIEA as coupling reagent; we chose HATU/DIEA which had been shown 













































































































































































































Scheme 1 Procedure for the synthesis of 1400-member MMP inhibitors on solid-phase.  
Reagents and conditions: (a) i:Fmoc-Lys(Biotin)-OH, HOBt, HBTU, DIEA, DMF, 12 hrs; 
ii: 20% piperidine/DMF, 2hrs; (b)i:Fmoc-Gly-OH, HOBt, HBTU, DIEA, 6 hrs; ii:20% 
piperidine/DMF, 2hrs; (c) i:Fmoc-Gly-OH, HOBt, HBTU, DIEA, 6 hrs; ii: 20% 
piperidine/DMF, 2hrs;  (d) i:Fmoc-AA3-OH, HOBt, HBTU, DIEA, 8 hrs; ii: 20% 
piperidine/DMF, 2hrs; (e) i:Fmoc-AA2-OH, HOBt, HBTU, DIEA, 8 hrs; ii: 20% 
piperidine/DMF, 2hrs; (f) i:CPh3ONH-Suc(2-P1’)-COOH, 1% Fmoc-ACC-COOH, 
HATU, 2,4,6-collidine or (HOBt, HBTU, DIEA), 12 hrs; ii: 20% piperidine/DMF, 2hrs; 
(g) 95% TFA/ 5% TIS, 2hrs. 
 
2.4 Activity-Based High-Throughput Profiling of Metalloprotease Inhibitors  
Using Small Molecule Microarrays 
 
          Small molecule microarrays have surfaced as important tools for screening large 
chemical libraries against a variety of protein targets for the rapid discovery of bioactive 
compounds.40 , 24 This method has generally involves the immobilization of libraries of 
compounds in addressable grids on glass slides, onto which fluorescently tagged proteins 
are applied in attempts to isolate the strongest binders. The major limitation of such high-
18 
throughput screening systems lies not so much in hit identification as in hit validation. 
Screening merely based on simple ligand binding potency invariably introduces false 
positives; arising as a result of inconsequential affinity to non-targeted regions of the 
protein. Without time-consuming validation, it remains unconfirmed whether any of the 
initial “hits” detected on traditional array platforms is relevant to the desired biological 
context.  In order to address these existing limitations of small molecule microarrays in 
chemical screening, we have developed an alternative approach that allows small 
molecule modulators of protein function to be directly evaluated on the microarray, in an 
activity-based manner. By pre-coating slides with fluorogenic enzyme substrates, 
followed by programmed application of premixed enzyme and libraries of putative small 
molecule modulators (Scheme 2), we had been able to take advantage of the high-
thoughput, miniaturized microarray platform and at the same time directly isolate specific 
small molecules with high inhibition potency. Furthermore our strategy does not require 
tagging of the enzyme with a fluorophore, or secondary detection using antibodies, 
allowing proteins to be evaluated in their native form, and in real-time.  
 
Low fluorescence
Print mixtures of 









Bodipy FL casein +
Scan to detect fluorescence  
 
Scheme 2 Nanodroplet SMM strategy for high-throughput profiling of potential MMP 
inhibitors. 
 
      
19 
          We next used the nanodroplet strategy to screen the 400 hydroxamates against 
thermolysin and collagenase, as they exhibit similarity to many vertebrate 
metallopeptidases, in particular to those of the MMP family.41 , 32e  To validate our results, 
separate experiments were performed in standard microplate format. Advantages of the 
approach were immediately evident. First, the entire 400-member library (in duplicate) 
was readily accommodated on a single slide, effectively allowing >800 assays to be 
performed with merely 6 ml of bodipy FL casein (Figure 12 a). With few exceptions, 
results obtained from SMM and microplate formats were in good agreement, giving a 
relatively high Pearson correlation coefficient (r = 0.852). Second, the relative potency of 
each inhibitor was immediately revealed by the fluorescence intensity generated from its 
corresponding nanodroplet (small boxes in Figure 12 a) with more potent inhibitors 
giving weaker fluorescence signals, thus avoiding tedious hit validation. This was 
unambiguously confirmed by enzyme kinetic experiments carried out in microplates on 
selected inhibitors. Notably, the nanodroplet SMM strategy was able to discern slight 
differences in inhibitor potency. Finally, because the enzyme ‘‘inhibitor fingerprint’’ was 
generated in a single experiment under uniform conditions, the results could be used 
directly for further SAR analysis to address not only potency, but more importantly 
selectivity, of any given inhibitor (Figure 12 b): the dendrograms, before (left) and after 
(right) cluster analysis, show the relative potency of each inhibitor against thermolysin 
with regards to its P2’ and P3’ substitutions. Our results indicate that Cys, Glu and Asp 
were disfavored at both P2’ and P3’ positions. Potent thermolysin inhibitors appear to be 
those containing aromatic (i.e. Trp/Tyr), small (i.e. Ala), hydrophobic (i.e. Leu/Ile), basic 
(i.e. Lys/ Arg) and polar (i.e. Gln/Asn) residues in a variety of P2’/ P3’ combinations, with 
20 
considerable variations across rows and columns, indicating cooperativity from both P2’ 
and P3’ residues is critical to achieve maximum inhibition. Interestingly, screening results 
obtained with collagenase were distinctly different from those with thermolysin, with 
potent inhibitors comprising predominantly aromatic (i.e. Tyr/Trp/Phe) and hydrophobic 
residues (i.e. Leu/Ile) at the P2’ position, and Trp at the P3’ position. This underlines the 
potential of our platform in detecting subtle substrate preferences amongst different 
MMPs. One of the most potent inhibitors identified from our screen was HONH–Suc(2-
iBu)–Tyr–Lys–Gly–Gly–Lys(Biotin)–CONH2 (IC50 =9.9 nM; Ki = 2.4 nM), consisting of 
Tyr and Lys at its P2’ and P3’ sites, respectively, and was 10-fold more potent than 
GM6001.This finding, to our knowledge, provides the first direct evidence of P2’/ P3’ 
selectivity in thermolysin inhibitors. It is further supported by inspection of the active site 
structure of thermolysin, showing predominantly hydrophobic S2’ and solvent-accessible 
S2’ pockets. 
 



























































































































































Figure 12 (a) Microarray image of the 400-member library screened against thermolysin. 
Samples were spotted in duplicate. Spots of selected inhibitors (labeled by their P2’–P3’ 
sequence) with IC50 (in brackets) were boxed. (b) Image in (a) shown as dendrogram 
before (left panel) or after Cluster Analysis (right panel) based on inhibition potency. See 
Supporting Information for details. 
 
         In conclusion, we have developed a nanodroplet SMM strategy for high-throughput 
profiling of inhibitors against metalloproteases, potentially extendable to other enzymes. 
It enables potent and highly selective inhibitors to be directly identified without the need 
of time-consuming hit validation. Our strategy thus provides a new tool in the ever 
expanding SMM technologies for the inhibitor fingerprinting of enzymes. 
Notwithstanding, a key issue remains to be addressed before the technique can be applied 
for routine high-throughput screening of enzyme inhibitors; with the current method, 
inhibitor/enzyme mixtures are individually prepared before spotting, and the microarray 
is processed immediately post-spotting. This inevitably limits the throughput of the 
screening, especially with multiple enzymes. We are currently investigating possible 























3.1 MMPI library design using click chemistry 
      “Click Chemistry” is a concept originally introduced by Sharpless et al which refers 
to several classes of chemical transformations that share a number of important properties 
including very high reaction efficiency (in both conversion and selectivity) under mild 
conditions, and a simple workup.42 The Cu(I)-catalyzed 1,3-cycloaddition between an 
azide and an alkyne is one such reaction that has recently been explored in the discovery 
of drugs and materials. This strategy has been successfully applied to the synthesis and 
identification of inhibitors against a number of biological targets, including HIV protease, 
43 a, 44b sulfotransferases,44c fucosyltransferases,44d protein tyrosine phosphatases,44e 
acetylcholinesterase 44f and others.44g Herein, we describe, for the first time, a “click 
chemistry” approach for the rapid synthesis/assembly of a small molecule library based 
on different succinyl hydroxamates and its subsequent in situ screening for identification 
of candidate hits which possess moderate inhibitory activity against MMPs over other 
metalloproteases. Our approach thus lays the foundation for future exploration of more 
potent and selective MMP inhibitors, in high throughput, using “click chemistry”.  
 
     Our library design was based on the general structure of hydroxamate-based MMP 
inhibitors (Figure 13), which were previously shown that (1) hydrophobic P1’ residues 
are in general preferred, (2) a variety of substitutions are tolerated at P2’ and P3’ 
positions, (3) hydrophobic P4’ residues are preferred and sometimes could confer a good 


































Figure 13 Structure of (top) general hydroxamate inhibitors and (bottom) “click 
chemistry” inhibitors reported herein against MMPs.  
  
 
3.2 Rapid assembly and in situ screening of metalloprotease inhibitors 
           Starting from the eight hydrophobic warheads (6A-6H) which we previously 
synthesized, a total of eight succinyl hydroxamates (AlkyneA-AlkyneH) bearing a 
variety of alkyl, cycloalkyl and aromatic side chains were synthesized as shown in 
Scheme 3.2. A common alkyne handle was introduced to each warhead, facilitating the 
subsequent assembly with twelve different azides (Azide1-Azide12) using “click 
chemistry” (Scheme 3). The azides which bearing a hydrophobic moiety connected via a 
linker with a varying alkyl length (n = 2-4) were synthesized via a highly efficient two 
step procedures as described. 44e By changing the linker length of the azides, our aim is to 
project the hydrophobic moiety into the P4’ or even P5’ binding pocket of a targeted 
MMP, thus improving both potency and specificity of the resulting inhibitors. With both 
the alkyene and azide building blocks available, a 96-member inhibitor library was 
assembled using “click chemistry” in a 96-deep well block. Each of the eight alkyne 
warheads was mixed with each of the twelve azides (in slight excess) in a tBuOH/H2O 
solution, followed by addition of catalytic amounts of sodium ascorbate and CuSO4. The 
24 
“click chemistry” proceeded with high efficiency at room temperature for > 12 hours 
before analysis by LC-MS; results indicated, in almost all cases, the complete 
consumption of the alkynes and quantitative formation of the desired triazole products, 
thus ensuring that they may be used directly for subsequent in situ enzymatic screening 
without any further purification. Screens of the bidentate compounds against 
representative metalloproteases provided discerning inhibition fingerprints, revealing 
compounds with low micromolar potency against MMP-7. The relative ease and 
convenience of the strategy in constructing focused chemical libraries for rapid in situ 































































       MMP-7 is one of the few MMPs that is secreted by cancer cells, and contributes to 
proliferation of intestinal adenomas as well as pancreatic cancer. 44 It was chosen for this 
study, together with collagenase and thermolysin that have roles in the progression 
bacterial corneal keratitis and the metabolism of Bacillus spp., respectively.45  It was 
screened in a high-throughput, automated fashion against the 96-member library panel 
using standard fluorescence assays in microplates. The inhibitor potency was evaluated 
from the reduction in fluorescence output when introduced in standard enzymatic assays 
with quenched substrates. The resulting inhibition fingerprints obtained are displayed in 
25 
Figure 14 a, demonstrating how such enzymes may be easily discerned through their 
unique inhibition “barcodes”, which differ from previous fingerprint profiles generated 
by other methods 46 in that our current method is able to directly reflect an enzyme’s 
inhibition profiles (potency and selectivity). By taking advantage of such inhibition 
fingerprints, it would become possible to characterize and group proteins in an activity-
dependent manner. Furthermore, such analysis may prove useful in distinguishing not 
only inhibitors that are potent against specific enzyme classes, but also those that provide 
good discriminatory potential, thereby minimizing off-target effects of potential drug 
candidates.  
 
     A broader evaluation of the inhibition profile obtained against MMP-7 (as shown in 
Figure 14 b) revealed a unique and consistent trend. Hydroxamate warheads containing 
alkyl and cycloalkyl side chains at the P1’ position (i.e. isobutyl, cyclohexyl and 
cyclopentyl in AlkyneB, AlkyneF and AlkyneG, repesctively) contributed highly to 
potency of inhibitors against MMP-7. The strongest inhibition was observed for scaffolds 
containing the latter two unnatural cyclic analogues. This correlates well with generic 
inhibitors against metalloproteases such as GM6001 and batimastat that are designed 
with a small hydrophobic residue (Leu), i.e. isobutyl in the P
1
’ 
pocket. 47 Our results thus 
highlight the potential of such pharmacophores in the design novel inhibitors against 
MMP-7 and possibly other MMPs. Another observation is that, azides having a 4-canbon 
linker (n = 4; F8-11, G8-11 in Figure 3b) appeared to contribute negatively to the 
inhibitor potency, which indicates the linker might be too long to properly accommodate 
the hydrophobic moiety of the azides into P
4
’ 
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Figure 14 (a) Inhibitor fingerprints of I) MMP-7, II) thermolysin and III) collagenase - 
represented as “barcodes”. Black: min inhibition; Red: max inhibition. Black: min 
inhibition; Red: max inhibition.  (b) Screening of “clicked” inhibitors against MMP-7. 
Heat map obtained using TreeView displays the inhibition fingerprint, with most potent 
inhibitors indicated in bright red. 
 
       To unambiguously confirm the potency of these scaffolds from the preliminary 
screen, two compounds, F5 and G6, representing each of the cyclohexyl and cyclopentyl 
warheads were selected for detailed evaluations. These molecules were purified and fully 
characterized by NMR and LC-MS, before being evaluated against the panel of 
metalloproteases to elucidate the relevant inhibition constants. As shown in Table 3.2, F5 
and G6 indeed inhibited MMP-7 strongly with a K
i 
of 1.4 μM and 3.8 μM respectively. 
More importantly, these inhibitors were 10 to 35 times more potent towards MMP-7 than 
the bacterial metalloproteases tested, demonstrating the potential of the strategy in 





 Table 1  IC50 (in μM) and Ki (in μM) of selected inhibitors 
 
   MMP-7 thermolysin collagenase 
 Ki IC50 IC50 IC50
F5 3.8 12.5 >50 >50 


























































Chapter 4 Activity-based Metalloprotease Profiling 
 
 
4.1 Designing affinity-based matrix metalloprotease probes 
          With the precise biological functions of most human MMPs remaining largely 
unknown, the development of novel chemical and biological methods capable of high-
throughput identification and characterization of MMPs has become increasingly urgent. 
Activity-based profiling, originally developed by Cravatt et al, 30 is one such technique 
that has recently been adapted for the study of metalloproteases including MMPs.48 ABP 
works by selectively targeting enzymes of choice from a crude proteome, in an activity-
based manner, using the so-called activity- and affinity-based small molecule probes. In 
the case of MMPs, small molecule probes possessing a) a hydroxamic acid recognition 
moiety known to chelate to the actives-site zinc of MMPs (as well as other zinc-
containing proteins such as Thermolysin and Collagenase), b) a photolabile group 
(usually benzophenone or diazirine) capable of covalent crosslinking to the target enzyme, 
and c) a fluorescent/affinity tag for easy visualization/isolation of the cross-linked 
enzyme, have been successfully documented.32d, 42b Furthermore, in cases where a 
repertoire of probes having different recognition elements is available, one can obtain the 
“activity-based fingerprint” of the target enzyme, which reveals not only affinity, but 
more importantly specificity, of the enzyme/probe complex. We previously reported first-
generation MMP probes which were peptides containing a C-terminal hydroxamic 
acid.42b Despite simplicity in their chemical synthesis, these so-called “left-handed” 
probes suffer a major drawback in that they bind to MMPs with relatively low affinity, 
making them less suitable for sensitive detection of MMPs from a complex proteome. In 
this project, we demonstrate 1) the synthesis of second-generation “right-handed” probes 
29 
aided by “click chemistry” (Figure 15) 2) their application in gel-based activity-based 
fingerprinting of numerous metalloproteases (including MMPs), and 3) the related 
preliminary microarray-based experiments, which, for the first time, demonstrate affinity-
based probes are indeed compatible with protein microarrays for potential enzyme 
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Figure 15 Structures of second generation MMP probes  
 
 
4.2 Activity based fingerprinting of metalloprotease 
          Protein fingerprinting, by its name suggests, is a distinctive pattern generated 
against a panel of focused small molecule probes, which reflects the protein’s catalytic 
activity or binding property. Since our probes were designed based on known inhibitors 
of metalloproteases, the resulting inhibitor-based fingerprint not only offers invaluable 
information for decoding the enzymes’ physiological roles, but also facilitates the 
discovery of potent and selective inhibitors as potential drugs. A diverse group of 
different classes of metalloproteases were chosen in our experiment, such that they 
highlight the potential of the strategy not only in distinguishing between both close and 
distant members, but also in potential identification and characterization of various 
disease-related enzymes, i.e. MMPs and anthrax lethal factor. In additon, carbonic 
30 
anhydrase, a well-known zinc-binding protein (but not a metalloprotease) was also tested. 
Figure 16 displays the results obtained using gel-based fingerprinting with the probe 
library. Notably, we were able to produce distinct and reproducible fingerprints for each 
of these proteins, thus providing a unique capability of identifying and classifying these 
proteins according to their labeling profiles. Generally the Lys and Ile probes showed the 
greatest degree of labeling and seemed to strongly label nearly all the enzymes tested. 
The other probes were however more discerning in their labeling patterns. It was 
observed that the strongest labeling for MMP-3 was that of Long-OH and Lys probes. 
This agrees well with the known long hydrophobic pocket of MMP-3 that has been 
previously reported to bind designed inhibitors with such long hydrophilic scaffolds.
 
MT-
1 MMP also shares a similar long pocket as MMP-3 and is observed to possess greater 
affinity to the Long-Phe as well as the Lys probe relative to the other probe scaffolds. 
The short S1’ pocket of MMP-7 was shown to accommodate both the Val and Phe 
probes. The Asp and Sulfone probes showed the weakest labeling with most of the 
enzymes, indicating these moieties are generally unfavoured for most of the 
metalloproteases tested. Overall the fingerprints enabled different enzymes to be 
classified according to their similarity. MMP-3 gave a distinct profile compared to the 
other enzymes screened. The labeling pattern of carbonic anhydrase was similar to that of 
MMP-7. Both Anthrax Lethal Factor and MT-1 MMP show strong selective labeling with 
one of the probe library set, namely Ile and Lys respectively. Importantly the panel of 
probes we have designed enables sufficient coverage for one enzyme to be distinguished 
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Figure 16 Fingerprints of 12 probes against 7 metalloenzymes. Strongest relative 
labeling is visualized in red according to the scale shown.  
 
 
         We next tested the feasibility of these probes to be used in a protein microarray for 
potential high-throughput discovery of metalloproteases. Previously, only activity-based, 
and not affinity-based, probes have been shown to detect enzymes immobilized in a 
protein microarray.47c,
 49 Five different enzymes, of which three metalloproteases (i.e. 
Collagenase, Thermolysin and Anthrax LF), one serine protease (i.e. β-Chymotrypsin) 
and carbonic anhydrase, were spotted in triplicate on a glass slide, and subsequently 
screened with the Leu probe (Figure 17). Results indicate that the probe was in general 
able to distinguish metalloenzyme activity over other non-metalloenzyme activities, in 
most cases generating positive fluorescence signals only with metalloproteases (e.g. 
Collagenase and Thermolysin), as well as carbonic anhydrase (a zinc-binding enzyme), 
but not with β-Chymotrypsin. Despite several attempts, we were unable to detect the 
fluorescence labeling of Anthrax LF, as well as several MMPs (data not shown), on the 
microarray. As these proteins were only available from commercial sources in very low 
stock concentrations, we attibuted our failure to the less-than-optimal immobilization of 
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Figure 17 Protein microarray of various metalloenzymes screened by the Leu probe. 
Five different proteins were spotted in triplicate: 1. Carbonic anhydrase (300 μg/ml); 2. 
Collagenase (300 μg/ml); 3. Thermolysin (300 μg/ml); 4. Anthrax LF (6 μg/ml); 5. β-
Chymotrypsin (300 μg/ml).  
 
          In conclusion, we have used “click chemistry” to successfully synthesize a second-
generation library of metalloprotease probes containing succinyl warheads with a variety 
of  P1’ functionalities. With these probes, we have been able to generate unique activity-
based fingerprints against various metalloproteases including MMPs and other 
therapeutically important enzymes such as anthrax LF. Such fingerprinting strategies may 
lead to future identification and characterization of new MMPs, and the development of 
potential potent and selective inhibitors. We have also for the first time shown that 
affinity-based probes may be equally amenable for high-throughput screening of 
metalloprotease activities in a protein microarray.  
 
  
4.3 Perspective-Activity based metalloprotease probes 
        Despite the success of utilizing photo-labile group (benzophenone or diazarine) for 
covalent linking the probe with target metalloprotease, the labeling mechanism is still 
affinity-based, which means their interaction is not based on the enzyme’s catalytic 
mechanism. The major drawback of affinity-based probe is non-specific labeling 
contributing to interfering background signals. Presently, all the MMP probes designed 
33 
exhibit their inhibitory activity by chelation to the catalytic zinc ion. MMPs differ from 
cysteine and serine proteases in that the nucleophile of MMP hydrolysis is a zinc 
bounded water molecule, which is not part of the enzyme and thus cannot be utilized for 
reaction with inhibitors or probes. However upon closer examination, it is found that 
there is a glutamic acid residue at the catalytic site which is involved in hydrogen 
bonding to the nucleophilic water molecule. The glutamic acid, like the –SH and –OH 
groups in cysteine and serine proteases respectively, can serve as a nucleophile for 
covalent modification. Several irreversible metalloprotease inhibitors based on modifying 
the active site glutamic acid have been reported, (Scheme 4)50 which could be used as a 























Scheme 4 Mechanism of acetals as latent electrophiles that interact with catalytic 
nucleophile at the active site of  matrix metalloproteases.  Firstly, the biphenyl moiety is  
projected into the deep hydrophobic pocket in the active sites of gelatinases, and this 
process brings the thiirane moiety close to the active-site zinc ion. Finally, the active site 



















Chapter 5 Experimental Section 
 
 
5.1 General Information 
    Starting materials and reagents were purchased commercially and used without 
further purification, unless otherwise stated. All moisture-sensitive reactions were 
performed under a positive pressure of nitrogen. 1HNMR spectra were recorded on a 300 
MHz Bruker ACF300 or DPX300 NMR spectrometer, Chemical shifts are reported in 
parts per million referenced to internal standard ((CH3)4Si = 0.00 ppm). ESI mass spectra 
were acquired in the positive mode using a Finnigan/Mat TSQ7000 spectrometer. 
Analytical RP-HPLC separations were performed on Phenomex C18 (150 x 3.0 mm) 
column, using a Shimadzu Prominence HPLC system equipped with a Shimadzu SPD-
20A detector. Eluents A (0.1 % TFA/acetonitrile) and B (0.1 % TFA/water) were used as 
the mobile phases. Thermolysin (E.C. 3.4.24.27) and GM6001 were purchased from 
Calbiochem (USA) and Bacterial collagenase (E.C. 3.4.24.3) was purchased from Sigma-
Aldrich (Milwauki, USA) at the highest grade available and used without further 
purification.  
 
5.2 Synthesis of succinyl hydroxamate-based warhead bearing hydrophobic side 
chains 
 Synthesis of mono-substituted succinyl hydroxamate involved five steps (Scheme 
5). First the acid was condensed with 2-oxazolidone in the presence of DCC/DMAP. This 
step was quite efficient and gave ~90% high yield. Subsequently, reaction of the 
oxazolidinone 2 with sodium hexamethyldisilazide and then tert-butyl bromoacetate 
35 
produced the racemic alkylated product 3 in ~80% yield. Deprotection of the tert-butyl 
ester followed by coupling with trityl hydroxylamine generated the succinyl hydroxamate 
5 in ~70% yield over two steps. Removal of the oxazolidone protection group with 
lithium hydroxide/hydrogen peroxide produced the desired racemic monosubstituted 
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Scheme 5 Synthesis route of hydrophobic MMPI warheads. 
General procedure for the coupling reaction of acids 1 with 2-oxazolidinone:51
To a suspension of 2-oxazolidinone (5.30 g, 60 mmol), DMAP (0.96 g, 7.8 mmol) 
and 1 (78 mmol) in CH2Cl2 (100 mL) at 0 °C, under a nitrogen atmosphere, was added 
DCC in one portion (16.1 g, 78 mmol). After 10 min the temperature was raised to RT 
and stirring was continued overnight. The dicyclohexylurea formed was filtered and the 
precipitate washed with CH2Cl2 (20 ml). The filtrate was washed with sat. NaHCO3 (100 
ml), dried with Na2SO4 and concentrated at reduced pressure to furnish the crude product, 
which was purified by silica gel chromatography (20%-30% EtOAc in hexanes) to afford 
2 as a colorless oil. 
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General procedure for the alkylation of oxazolidinone 2 with tert-butyl 2-bromoacetate:52
             To a flame-dried 500 ml three-necked RBF was added 9.26 g (50 mmol) of 
oxazoline 2 in 100 ml of dry THF. This mixture was cooled to -78oC, and 1.0 M sodium 
bis(trimethylsilyl)amide in THF (65 ml, 65 mmol) was added dropwise. The internal 
reaction temperature was kept below -71 
o
C. The solution was then stirred at -78 oC for 1 
hour, then neat tert-butyl bromoacetate (11.1 ml, 75 mmol) was added via a syringe over 
a 10-minute period. The mixture was stirred at -78 oC for 2 hours then warmed to 0oC and 
quenched with Et2O and aqueous 2 M NH4Cl. The aqueous layer was separated and 
extracted with diethyl ether. The combined organic layers were washed with brine, dried, 
filtered, and concentrated to give a brown oil. The oil was purified by silica gel 
chromatography (15%-20% EA in hexane) to isolate desired product 3 as a colorless oil. 
 
General procedure for the cleavage of the tert-butyl group in 3: 
Compound 3 (40 mmol) was dissolved in 320 ml of DCM, then TFA (30.6 ml, 
400 mmol) was added, the mixture was vigorously stirred at room temperature for 4 
hours. After removal of the solvent, the product was diluted with ethyl acetate (100 ml), 
then washed with water and brine, followed by drying in Na2SO4. The solution was 
concentrated to give the corresponding carboxylic acid 5 as a brownish oil, which was 
dried in vacuo for 4 hours to completely remove TFA. 
 
General procedure for the coupling of carboxylic acids 4 with trityloxyamine: 
           Carboxylic acid 4 (50 mmol) in DCM (150 ml) was cooled down to 0oC, before 
addition of DCC (12.4 g, 60 mmol). Ten minutes later, the trityl-protected hydroxyamine 
(14.6 g, 60 mmol) was subsequently added to the reaction mixture, and the mixture was 
allowed to warm up to room temperature and stirred for 3 hours. The dicyclohexylurea 
formed was filtered and the filtrate was washed with saturated NaHCO3, brine, dried over 
Na2SO4, then concentrated to give a brown oil, which was purified by silica gel 
chromatography (20%-30% EA in hexane) to isolate the desired product 5 as a white 
solid. 
 
General procedure for the hydrolytic cleavage of the 2-oxazolidinone moiety in 5: 
To imide 5 (35 mmol) in 4/1 THF/H2O (600 ml) was added 30% aqueous H2O2 (14.3 ml, 136 mmol) at 0oC over 5 minutes. The internal temperature was kept at or 
below 5oC. Lithium hydroxide (2.8 g, 116.7 mmol) in 20 ml of water was then added 
over 5 minutes to ensure the internal temperature was kept below 4oC. After addition, the 
mixture was allowed to warm to room temperature. After two hours, the reaction mixture 
was cooled to 0oC and sodium nitrite (7.2 g, 103.7 mmol.) was added. The mixture was 
allowed to warm to room temperature and concentrated under reduced pressure. The 
resulting liquid was extracted with CHCl3. The combined organic layers were washed 
with aqueous 0.1 M NaOH. The combined aqueous layers were acidified with aqueous 1 
M HCl to pH = 7, then extracted with ethyl acetate. The combined organic layers were 
dried, filtered, and concentrated to give 6 as an off-white solid. 
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3-(3-methylbutanoyl)oxazolidin-2-one (2A):  
Yield = 88%. 1H-NMR (300 MHz, CDCl3) δ 4.41 (t, J = 8.34 Hz, 2H), 4.05 (t, J = 
8.37 Hz, 2H), 2.81 (d, J = 6.96 Hz, 2H), 2.30 – 2.08 (m, 1H), 0.98 (d, J = 6.60 Hz, 6H); 
ESI-MS: m/z [M+Na]+ = 194.0.  
 
3-(4-methylpentanoyl)oxazolidin-2-one (2B):  
Yield = 93%. 1H-NMR (300 MHz, CDCl3) δ 4.26 (t, J = 16.1 Hz, 2H), 3.85 (t, J = 
16.1 Hz, 2H), 2.73 (t, J = 15.2 Hz, 2H), 1.50-1.33 (m, 3H), 0.77 (d, J = 7.2 Hz, 6H); ESI-
MS cald for C9H15NO3Na [M+Na]+
 
=208.2, found 208.0. 
 
 
3-(3-methylpentanoyl)oxazolidin-2-one (2C):  
Yield = 76 %. 1H -NMR (300 MHz, CDCl3) δ 4.37 (t, J = 8.01 Hz, 2H), 3.98 (t, J 
= 8.03 Hz, 2H), 2.91 – 2.84 (dd, J = 16.02 Hz, J = 5.58 Hz, 1H), 2.74 – 2.66 (dd, J = 
16.00 Hz, J = 7.98 Hz, 1H), 2.00 – 1.87 (m, 1H), 1.46 – 1.32 (m, 1H), 1.28 – 1.12 (m, 
1H), 0.96 – 0.82 (m, 6H); ESI-MS: m/z [M+Na]+ = 208.2.  
 
3-(3-phenylpropanoyl)oxazolidin-2-one (2D):  
Yield = 91%. 1H-NMR (300 MHz, CDCl3) δ 7.34 – 7.19 (m, 5H), 4.38 (t, J = 8.01 
Hz, 2H), 4.00 (t, J = 8.01 Hz, 2H), 3.26 (t, J = 7.49 Hz, 2H), 2.99 (t, J = 7.50 Hz, 2H); 
ESI-MS: m/z [M+Na]+= 242.2.  
 
3-(5-phenylpentanoyl)oxazolidin-2-one (2E):  
Yield = 82%. 1H-NMR (300 MHz, CDCl3) δ 7.42 – 7.04 (m, 5H), 4.38 (t, J = 8.01 
Hz, 2H), 3.99 (t, J = 8.01 Hz, 2H), 2.95 (m, 2H), 2.65 (t, J = 6.96 Hz, 2H), 1.73 – 1.68 (m, 
4H); ESI-MS: m/z [M+Na]+= 270.3.  
 
3-(2-cyclohexylacetyl)oxazolidin-2-one (2F):  
Yield = 95%. 1H-NMR (300 MHz, CDCl3) δ 4.39 (t, J = 8.19 Hz, 2H), 4.01 (t, J = 
8.19 Hz, 2H), 2.80 (d, J = 6.96 Hz, 2H), 2.01 – 1.79 (m, 1H), 1.79 – 1.54 (m, 5H), 1.38 – 
0.86 (m, 5H); ESI-MS: m/z [M+Na]+ = 234.3.  
 
3-(3-cyclopentylpropanoyl)oxazolidin-2-one (2G):  
Yield = 70%. 1H-NMR (300 MHz, CDCl3) δ 4.38 (t, J = 8.01 Hz, 2H), 3.99 (t, J = 
8.19 Hz, 2H), 2.89 (t, J = 7.67 Hz, 2H) 1.77 – 1.64 (m, 3H), 1.62 – 1.47 (m, 6H), 1.11 – 
1.09 (m, 2H); ESI-MS: m/z [M+Na]+ = 234.2.  
 
3-(4-(benzyloxy)butanoyl)oxazolidin-2-one (2H):  
Yield = 82%. 1H-NMR (300 MHz, CDCl3) δ 7.38-7.26 (m, 5H), 4.47 (s, 2H), 4.29 
(t, J = 8.37 Hz, 2H), 3.99 (t, J = 8.37 Hz, 2H), 3.55 (t, J = 6.27 Hz, 2H), 3.03 (t, J = 7.32 
Hz, 2H), 1.98 (t, J = 6.63 Hz, 2H). ESI-MS: m/z [M+Na]+ = 286.2.  
 
tert-butyl 4-methyl-3-(2-oxooxazolidine-3-carbonyl)pentanoate (3A):  
Yield = 66%. 1H-NMR (300 MHz, CDCl3) δ 4.39 (t, J = 7.32 Hz, 2H), 4.09 – 3.98 
(m, 3H), 2.82 – 2.78 (m, 1H), 2.41 – 2.35 (dd, J = 16.87 Hz, J = 3.15 Hz, 1H), 2.03 – 
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1.94 (m, 1H), 1.40, (s, 9H), 0.99 – 0.97 (m, 3H), 0.87 (d, J = 6.96 Hz); ESI-MS: m/z 
[M+Na]+ = 308.2.  
 
tert-butyl 5-methyl-3-(2-oxooxazolidine-3-carbonyl)hexanoate (3B):  
Yield = 83%. 1H-NMR (300 MHz, CDCl
3
) δ 4.37 (t, J = 17.2 Hz, 2H), 4.20-4.10 
(m, 1H), 3.97 (t, J = 17.2 Hz, 2H), 2.63 (q, 1H), 2.35 (q, 1H), 1.52-1.48 (m, 2H); 1.35 (s, 
9H), 1.17-1.24 (m, 1H), 0.84 (q, 4H). ESI-MS cald for C15H25NO5Na [M+Na]+ =322.3, 
found 322.1.  
 
tert-butyl 4-methyl-3-(2-oxooxazolidine-3-carbonyl)hexanoate (3C):  
Yield = 88%. 1H-NMR (300 MHz, CDCl3) δ 4.40 – 4.34 (m, 2H), 4.12 – 3.94 (m, 
3H), 2.86 – 2.72 (m, 1H), 2.38 – 2.25 (m, 1H), 1.47 – 1.32 (m, 1H), 1.37 (s, 9H), 1.28 – 
1.14 (m, 2H), 0.92 – 0.77 (m, 6H); ESI-MS: m/z [M+Na]+ = 322.1.  
 
tert-butyl 3-benzyl-4-oxo-4-(2-oxooxazolidin-3-yl)butanoate (3D):  
Yield = 83%. 1H-NMR (300 MHz, CDCl3) δ 7.34 – 7.17 (m, 5H), 4.44 – 4.28 (m, 
3H), 4.08 – 3.88 (m, 2H), 3.08 – 3.02 (dd, J = 12.87 Hz , J = 5.58 Hz, 1H), 2.83 – 2.74 
(dd, J = 17.05, J = 11.16 Hz, 1H), 2.60 – 2.52 (dd, J = 13.06 Hz, J = 9.75 Hz, 1H), 2.33 – 
2.26 (dd, J = 17.07 Hz, J = 3.84 Hz, 1H), 1.37 (s, 9H); ESI-MS: m/z [M+Na]+ = 356.4.  
 
tert-butyl 3-(2-oxooxazolidine-3-carbonyl)-6-phenylhexanoate (3E):  
Yield = 85%. 1H-NMR (300 MHz, CDCl3) δ 7.31 – 7.11 (m, 5H), 4.41 – 4.32 (m, 
2H), 4.17 – 3.93 (m, 3H), 2.80 – 2.71 (dd, J = 16.71 Hz, J = 10.80 Hz, 1H), 2.66 – 2.51 
(m, 2H), 2.42 – 2.35 (dd, J = 16.71 Hz, J = 4.17 Hz, 1H), 1.78 – 1.58 (m, 4H), 1.35 (s, 
9H); ESI-MS: m/z [M+Na]+ = 384.4.  
 
tert-butyl 3-cyclohexyl-4-oxo-4-(2-oxooxazolidin-3-yl)butanoate (3F):  
Yield = 67%. 1H-NMR (300 MHz, CDCl3) δ 4.52 – 4.36 (m, 2H), 4.15 – 4.01 (m, 
3H), 2.86 – 2.77 (m, 1H), 2.50 – 2.43 (m, 1H), 1.74 – 1.63 (m, 6H), 1.43 (s, 9H) 1.39 – 
0.94 (m, 5H); ESI-MS: m/z [M+H]+ = 326.4.  
 
tert-butyl 3-(cyclopentylmethyl)-4-oxo-4-(2-oxooxazolidin-3-yl)butanoate (3G):  
Yield = 74%. 1H-NMR (300 MHz, CDCl3) δ 4.43 – 4.38 (m, 2H), 4.24 – 4.15 (m, 
1H), 4.07 – 3.98 (m, 2H), 2.78 – 2.69 (dd, J = 16.53 Hz, J = 10.80 Hz, 1H), 2.49 – 2.42 
(dd, J = 16.53 Hz, J = 4.17 Hz, 1H), 1.80 – 1.66 (m, 3H), 1.66 – 1.47 (m, 6H), 1.40 (s, 
9H), 1.18 – 1.00 (m, 2H); ESI-MS: m/z [M+Na]+ = 348.4.  
 
tert-butyl 5-(benzyloxy)-3-(2-oxooxazolidine-3-carbonyl)pentanoate (3H):  
Yield = 78%. 1H-NMR (300 MHz, CDCl3) δ 7.35 – 7.20 (m, 5H), 4.50 – 4.30 (m, 
2H), 4.30 – 4.20 (m, 2H), 4.17 – 3.81 (m, 2H), 3.69 – 3.52 (m, 3H), 2.87 – 2.76 (dd, J = 
16.5 Hz, J = 10.44 Hz, 1H), 2.85 – 2.76 (dd, J = 16.71 Hz, J = 4.53Hz, 1H), 2.09 – 1.98 
(m, 1H), 1.35 (s, 9H); ESI-MS: m/z [M+Na]+= 400.3.  
 
4-methyl-3-(2-oxooxazolidine-3-carbonyl)pentanoic acid (4A):  
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Yield = 98%. 1H-NMR (300 MHz, CDCl3) δ 4.50 – 4.39 (m, 2H), 4.12 – 3.98 (m, 
3H), 2.98 – 2.80 (m, 1H), 2.56 – 2.50 (dd, J = 17.60 Hz, J = 3.32 Hz, 1H), 2.16 – 2.03 (m, 
1H), 1.02 – 0.87 (m, 6H); ESI-MS: m/z [M-H]- = 228.3.  
 
5-methyl-3-(2-oxooxazolidine-3-carbonyl)hexanoic acid (4B):  
Yield = 99%. 1H-NMR (300 MHz, CDCl3) δ 4.44-4.37 (m, 2H), 4.28-4.12 (m, 
1H), 4.05-3.95 (m, 2H), 2.81 (q, 1H), 2.52 (q, 1H); 1.57-1.51 (m, 2H), 1.35-1.23 ( m, 1H), 
0.91(q, 4H); ESI-MS cald for C11H17NO5Na [M+H]
+ 
244.2, found 244.0.  
 
4-methyl-3-(2-oxooxazolidine-3-carbonyl)hexanoic acid (4C):  
Yield = 99%. 1H-NMR (300 MHz, CDCl3) δ 8.87 (br s,1H), 4.43 – 4.37 (m, 2H), 
4.14 – 3.92 (m, 3H), 2.95 – 2.69 (m, 1H), 2.54 – 2.37 (m, 1H), 2.20 – 1.68 (m, 1H), 1.45 
– 1.20 (m, 2H), 1.00 – 0.78 (m, 6H); ESI-MS: m/z [M-H]- = 242.4.  
 
3-benzyl-4-oxo-4-(2-oxooxazolidin-3-yl)butanoic acid (4D):  
Yield = 98%. 1H-NMR (300 MHz, CDCl3) δ 7.35 – 7.17 (m, 5H), 4.45 – 4.27 (m, 
3H), 4.08 – 3.87 (m, 2H), 3.12 – 3.06 (dd, J = 13.23 Hz, J = 5.22 Hz, 1H), 2.94 – 2.84 
(dd, J = 17.58 Hz, J = 10.80 Hz, 1H), 2.60 – 2.53 (dd, J = 13.23 Hz, J = 9.75 Hz, 1H), 
2.43 – 2.36 (dd, J = 17.42 Hz, J = 3.84 Hz, 1H); ESI-MS: m/z [M-H]- = 276.3.  
 
3-(2-oxooxazolidine-3-carbonyl)-6-phenylhexanoic acid (4E):  
Yield = 99%. 1H-NMR (300 MHz, CDCl3) δ 8.26 (br s, 1H), 7.42 – 7.15 (m, 5H), 
4.45 – 4.37 (m, 2H), 4.35 – 4.15 (m, 1H), 4.04 – 3.93 (m, 2H), 2.94 – 2.85 (dd, J = 17.42 
Hz, J = 10.44 Hz, 1H), 2.64 – 2.48 (m, 3H), 1.76 – 1.58 (m, 5H); ESI-MS: m/z [M-H]- = 
304.3.  
 
3-cyclohexyl-4-oxo-4-(2-oxooxazolidin-3-yl)butanoic acid (4F):  
Yield = 99%. 1H-NMR (300 MHz, CDCl3) δ 8.60 (br s, 1H), 4.45 – 4.38 (m, 2H), 
4.14 – 3.94 (m, 3H), 2.99 – 2.76 (m, 1H), 2.57 – 2.50 (m, 1H), 1.74 – 1.62 (m, 6H), 1.31 
– 0.82 (m, 5H); ESI-MS: m/z [M-H]- = 268.2.  
 
3-(cyclopentylmethyl)-4-oxo-4-(2-oxooxazolidin-3-yl)butanoic acid (4G):  
Yield = 97%. 1H-NMR (300 MHz, CDCl3) δ 8.15 (br s, 1H), 4.46 – 4.38 (m, 2H), 
4.27 – 4.12 (m, 1H), 4.00 (m, 2H), 2.91 – 2.82 (dd, J = 17.25 Hz, J = 10.80 Hz, 1H), 2.61 
– 2.55 (dd, J = 17.24 Hz, J = 4.17 Hz, 1H), 1.79 – 1.54 (m, 9H), 1.25 – 1.08 (m, 2H); 
ESI-MS: m/z [M-H]- = 268.4.  
 
5-(benzyloxy)-3-(2-oxooxazolidine-3-carbonyl)pentanoic acid (4H):  
Yield = 99%. 1H-NMR (300 MHz, CDCl3) δ 7.72 (br s, 1H), 7.46-7.28 (m, 5H), 
4.58-4.42 (m, 2H), 4.38 – 4.20 (m, 2H), 4.05-3.85 (m, 2H), 3.72-3.52 (m, 3H), 2.98 – 
2.85 (dd, J = 17.25 Hz, J = 10.80 Hz, 1H), 2.61 – 2.55 (dd, J = 17.24 Hz, J = 4.17 Hz, 
1H), 2.08-1.79 (m, 2H); δ ESI-MS: m/z [M-H]- = 320.3.  
 
4-methyl-3-(2-oxooxazolidine-3-carbonyl)-N-(trityloxy)pentanamide (5A):  
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Yield = 74%. 1H-NMR (300 MHz, CDCl3) δ 7.30 – 7.15 (m, 16H), 4.34 (t, J = 8.0 
Hz, 2H), 4.09 – 3.90 (m, 3H), 2.41 – 2.32 (m, 1H), 1.88 – 1.70, (1H, m), 1.46 – 1.27 (m, 
1H), 0.71 – 0.60 (m, 6H); ESI-MS: m/z [M+Na]+ = 509.2.  
 
5-methyl-3-(2-oxooxazolidine-3-carbonyl)-N-(trityloxy)hexanamide (5B):  
Yield = 70%. 1H-NMR (300 MHz, CDCl3) δ 7.66 (br s, 1H), 7.35 (s, 15H), 4.35 (t, 
J = 16.4Hz, 2H), 4.13-3.89 (m, 3H), 2.33 (q, 1H); 1.66 (br s, 1H), 1.36-1.07 ( m, 3H), 
0.82(m, 6H); ESI-MS cald for C30H32N2O5Na [M+Na]+
 
523.2, found 523.1.  
 
4-methyl-3-(2-oxooxazolidine-3-carbonyl)-N-(trityloxy)hexanamide (5C):  
Yield = 78%. 1H-NMR (300 MHz, CDCl3) δ 7.66 (br s, 1H), 7.42 – 7.28 (m, 15H), 
4.33 (t, J = 7.83 Hz, 2H), 4.01 – 3.70 (m, 3H), 2.46 – 2.33 (m, 1H), 2.04 – 1.86 (m, 1H), 
1.74 – 1.58 (m, 1H), 1.41 – 0.62 (m, 8H); ESI-MS: m/z [M+Na]+ = 523.6.  
 
3-benzyl-4-oxo-4-(2-oxooxazolidin-3-yl)-N-(trityloxy)butanamide (5D):  
Yield = 82%. 1H-NMR (300 MHz, CDCl3) δ 7.60 (br s, 1H), 7.38 – 7.19 (m, 20H), 
4.38 – 4.20 (m, 3H), 3.98 – 3.78 (m, 2H), 3.10 – 2.76 (m, 2H), 2.41 – 2.21 (m, 2H); ESI-
MS: m/z [M+Na]+ = 557.5.  
 
3-(2-oxooxazolidine-3-carbonyl)-6-phenyl-N-(trityloxy)hexanamide (5E):  
Yield = 81%. 1H-NMR (300 MHz, CDCl3) δ 7.71 (br s, 1H), 7.44 – 7.11 (m, 20H), 
4.34 – 4.29 (t, J = 8.37 Hz, 2H), 4.00 – 3.65, (m, 3H), 2.61 – 2.28 (m, 4H), 1.55 – 1.25 
(m, 4H); ESI-MS: m/z [M+Na]+ = 585.3.  
 
3-cyclohexyl-4-oxo-4-(2-oxooxazolidin-3-yl)-N-(trityloxy)butanamide (5F):  
Yield = 74%. 1H-NMR (300 MHz, CDCl3) δ 7.60 (br s, 1H), 7.49 – 7.28 (m, 15H), 
4.45 – 4.23 (m, 2H), 4.04 – 3.59 (m, 3H), 2.41 – 2.32 (m, 1H), 1.75 – 1.30 (m, 7H), 1.19 
– 0.78 (m, 5H); ESI-MS: m/z [M+Na]+ = 549.6.  
 
3-(cyclopentylmethyl)-4-oxo-4-(2-oxooxazolidin-3-yl)-N-(trityloxy)butanamide(5G):   
          Yield = 54%. 1H-NMR (300 MHz, CDCl3) δ 7.45 – 7.30 (m, 15H), 4.33 (t, J = 8.01 
Hz, 2H), 4.05 – 3.88 (m, 3H), 2.46 – 2.34 (m, 1H), 1.73 – 1.46 (m, 10H), 1.15 – 0.87 (m, 
2H); ESI-MS: m/z [M+Na]+ = 549.5.  
 
5-(benzyloxy)-3-(2-oxooxazolidine-3-carbonyl)-N-(trityloxy)pentanamide (5H):  
         Yield = 72%. 1H-NMR (300 MHz, CDCl3) δ 7.48-7.30 (m, 20H), 4.48-4.30 (m, 2H), 
4.25 – 4.13 (m, 2H), 3.98-3.82 (m, 2H), 3.52-3.38 (m, 3H), 2.47-2.25 (m, 1H), 2.12-1.98 
(m, 1H), 1.79-1.65 (m, 2H); ESI-MS: m/z [M+Na]+ = 601.5.  
 
2-isopropyl-4-oxo-4-(trityloxyamino)butanoic acid (6A):  
Yield = 76%. 1H-NMR (300 MHz, CDCl3) δ 7.80 (br s, 1H), 7.49 – 7.26, (m, 
15H), 2.74 – 2.59 (m, 1H), 2.45 – 2.15 (m, 2H), 1.82 – 1.68 (m, 1H), 1.06 – 0.66 (m, 6H); 
13C-NMR (75 MHz, CDCl3) δ 174.4, 171.9, 146.8, 129.3 – 126.5 (m), 82.2, 42.9, 28.7, 
27.7, 19.5, 17.4; ESI-MS: m/z [M+Na]+ = 440.3.  
 
4-methyl-2-(2-oxo-2-(trityloxyamino)ethyl)pentanoic acid (6B):  
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Yield = 80%. 1H-NMR (300 MHz, CDCl3) δ 7.46 (br s, 1H), δ 7.32 (br s, 15H), 
4.10 (q, 1H), 2.59-2.53 (m, 1H), 2.32-2.20 (m, 1H), 1.45-1.32 (m, 3H); 0.84(m, 6H); ESI-
MS cald for C27H29NO4Na [M+Na]+ 454.2, found 454.0.  
 
3-methyl-2-(2-oxo-2-(trityloxyamino)ethyl)pentanoic acid (6C):  
Yield = 70%. 1H-NMR (300 MHz, CDCl3) δ 7.43 – 7.28 (m, 16H), 2.95 – 2.86 (m, 
1H), 2.75 – 2.56 (m, 1H), 2.44 – 2.37 (m, 1H), 2.21 – 2.06 (m, 1H), 1.53 – 1.05 (m, 2H), 
0.98 – 0.69 (m, 6H); 13C-NMR (75 MHz, CDCl3) δ 175.1, 172.2, 146.8, 130.1-126.5 (m), 
82.1, 41.1, 34.6, 26.9, 26.8, 14.0, 11.7; ESI-MS: m/z [M+Na]+ = 454.2.  
 
2-benzyl-4-oxo-4-(trityloxyamino)butanoic acid (6D):  
Yield = 79%. 1H-NMR (300 MHz, CDCl3) δ 7.49 – 6.96 (m, 20H), 3.03 – 2.86 (m, 
1H), 2.59 – 2.42, (m, 2H), 2.09 – 1.92 (m, 1H), 1.69 – 1.52 (m, 1H); 13C-NMR (75 MHz, 
CDCl3) δ 174.5, 171.8, 146.8, 136.5, 129.3 – 127.2 (m), 82.1, 38.4, 36.1, 30.6; ESI-MS: 
m/z [M+Na]+ = 488.3.  
 
2-(2-oxo-2-(trityloxyamino)ethyl)-5-phenylpentanoic acid (6E):  
Yield = 65%. 1H-NMR (300 MHz, CDCl3) δ 7.38 – 7.22 (m, 21H), 2.59 – 2.43 (m, 
4H), 2.31 – 2.15 (m, 1H), 1.54 – 1.26 (m, 4H); 13C-NMR (75 MHz, CDCl3) δ 178.2, 
174.9, 146.8, 141.7, 130.0 – 125.5 (m), 82.2, 36.9, 35.4, 31.6, 30.6, 28.2; ESI-MS: m/z 
[M+Na]+ = 516.6.  
 
2-cyclohexyl-4-oxo-4-(trityloxyamino)butanoic acid (6F):  
Yield = 64%. 1H-NMR (300MHz, CDCl3) δ 7.33 – 7.18 (m, 15H), 3.16 – 2.91 (m, 
1H), 2.79 – 2.71 (m, 1H), 2.46 – 2.42 (m, 1H), 2.50 – 1.52 (m, 6H), 1.24 – 1.09 (m, 5H);  
13C-NMR (75 MHz, CDCl3) δ174.4, 171.9, 146.8, 130.0 – 126.5 (m), 82.0, 42.5, 38.6, 
30.2, 28.3, 27.7, 25.8; ESI-MS: m/z [M+Na]+ = 480.6  
 
2-(cyclopentylmethyl)-4-oxo-4-(trityloxyamino)butanoic acid (6G):  
Yield = 83%. 1H-NMR (300 MHz, CDCl3) δ 7.42 – 7.19 (m, 15H), 2.20 – 2.05 (m, 
3H), 1.41 – 1.26 (m, 9H), 1.14 – 0.68 (m, 2H); 13C-NMR (75 MHz, CDCl3) δ 176.2, 
173.0, 146.8, 128.5 – 127.0 (m), 92.8, 45.7, 37.9 – 36.6 (m), 32.4 – 31.9 (m), 25.0; ESI-
MS: m/z [M+Na]+ = 480.6.  
 
2-(2-(benzyloxy)ethyl)-4-oxo-4-(trityloxyamino)butanoic acid (6H):  
           Yield = 73%. 1H-NMR (300 MHz, CDCl3) δ 7.48 – 7.20 (m, 20H), 4.55 - 4.34 (m, 
2H), 3.62-3.36 (m, 2H), 2.61-2.57 (m, 1H), 2.41-2.30 (m, 1H), 2.22-2.15 (m, 1H), 1.82-
1.62 (m, 2H); 13C-NMR (75 MHz, CDCl3) δ 176.2, 173.0, 146.8, 128.5 – 127.0 (m), 92.8, 
45.7, 37.9 – 36.6 (m), 32.4 – 31.9 (m), 25.0; ESI-MS: m/z [M+Na]+ = 532.6.  
 
5.3 Synthesis of succinyl hydroxamate-based warheads with P1’ substitution 
mimicking nature amino acid sides 
 
5.3.1 Synthesis of warheads 6I and 6J  
 Synthesis of hydrophilic and acidic P1’ substituted warheads involves 7 steps. Both 
of them started with mono-protection of the diol 7. This was followed by PDC oxidation 
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of alcohol 8 to give carboxylic acid 9. Upon installing oxazolidinone, enolate chemistry 
was carried out to introduce the succinyl template, giving rise to 11 and 12, respectively. 
To synthesize warhead 6I, trityl-protected hydroxylamine was first coupled to 11 using 
standard DCC procedures, followed by selective removal of the benzyl group on the 
alcohol using Pd/C with H2 to give 13. Subsequently, the free alcohol was protected with 
the acid-labile trityl group, followed by base hydrolysis of oxazolidinone to give the final 
warhead 6I. To synthesize warhead 6J, the alcohol moiety in 12 was oxidized to the 
corresponding acid, followed by coupling with trityl-protected hydroxylamine, giving 14. 




















































































Scheme 6 Synthesis route of warhead 6I and 6J 
 
General procedure for the conversion of 7a-b to 8a-b:53
 
To a solution of the diol 7 (a or b; 120 mmol) in DCM (300 ml) was added Ag
2
O 
(41.7 g, 180 mmol) and benzyl bromide (15.7 ml, 132 mmol) at room temperature under 
a nitrogen atmosphere. The reaction was stirred further for 4 hrs before the solid was 
removed by filtration. The resulting filtrate was concentrated in vacuo and purified by 
flash chromatography (10 – 30% EA/hexane) to give 8 as a colorless oil.  
 
5-(benzyloxy)pentan-1-ol (8a):  
Yield = 84%. 1H-NMR (300 MHz, CDCl
3
) δ 7.40-7.25 (m, 5H), 4.50 (s, 2H), 3.58 
(t, J = 12.2 Hz, 2H), 3.48 (t, J = 12.9 Hz, 1H), 2.28 (s, 1H), 1.67-1.54 (m, 4H), 1.51-1.40 
(m, 2H); ESI-MS: m/z [M+Na]+
 
= 217.3.  
 
4-(benzyloxy)butan-1-ol (8b):  
Yield = 80%. 1H-NMR (300 MHz, CDCl
3
) δ7.48 – 7.21, (m, 5H), 4.49, (s, 2H), 
3.57 (t, J = 6.48 Hz, 2H), 3.48 (t, J = 5.93 Hz, 2H), 2.91 (br s, 1H), 1.70 – 1.57 (m, 4H); 
ESI-MS: m/z [M+Na]+= 203.2  
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General procedure for oxidation of 8a-b to 9a-b:54
 
To a solution of 8 (a or b; 96 mmol) in DMF (250 ml) at 0 ºC under a nitrogen 
atmosphere was added pyridinium dichromate (170.6 g, 453 mmol). The mixture was 
gradually raised to room temperature and stirred overnight. Water was subsequently 
added and the resulting mixture was extracted with ether. The combined ether layers were 
washed with brine, dried over Na2SO4, filtered and concentrated. The oil obtained was 
purified by flash chromatography (10 – 20% EA/hexane) to give 9.  
 
5-(benzyloxy)pentanoic acid (9a):  
Yield = 50%.1H-NMR (300 MHz, CDCl3) δ 9.96 (br s, 1H), 7.42-7.25 (m, 5H), 
4.51 (s, 2H), 3.50 (t, J = 10.8 Hz, 2H), 2.38 (t, J = 12.6 Hz, 1H), 2.71 (m, 4H); ESI-MS: 
m/z [M-H]-= 207.2.  
 
4-(benzyloxy)butanoic acid (9b):  
Yield = 64%.1H-NMR (300 MHz, CDCl3) δ 10.10 (br s, 1H), 7.42-7.30 (m, 5H), 
4.54 (s, 2H), 3.56 (t, J = 5.94 Hz, 2H), 2.51 (t, J = 6.96 Hz, 2H), 1.98 (t, J = 6.63 Hz, 2H). 
ESI-MS: m/z [M-H]-= 193.1.  
 
Procedures for conversion of 9a-b to 10a-b, then to 11 & 12:  
 
The synthesis of 11 and 12 from 9a-b was accomplished using procedures described 
previously. 
 
3-(5-(benzyloxy)pentanoyl)oxazolidin-2-one (10a):  
            Yield = 80%. 1H-NMR (300 MHz, CDCl3) δ 7.33-7.22 (m, 5H), 4.60 (s, 2H), 4.35 
(t, J = 16.2 Hz, 2H), 3.90 (t, J = 15.9 Hz, 2H), 3.50 (t, J = 12.9Hz, 2H), 2.96 (t, J = 12.9 
Hz, 2H), 1.82-1.67 (m, 4H); ESI-MS: m/z [M+Na]+
 
= 300.2.  
 
3-(4-(benzyloxy)butanoyl)oxazolidin-2-one (10b):  
            Yield = 82%. 1H-NMR (300 MHz, CDCl3) δ 7.38-7.26 (m, 5H), 4.47 (s, 2H), 3.56 
(t, J = 5.94Hz, 2H), 2.51 (t, J = 6.96 Hz, 2H), 1.98 (t, J = 6.63 Hz, 2H). ESI-MS: m/z 
[M+Na]+
 
= 286.2.  
 
6-(benzyloxy)-3-(2-oxooxazolidine-3-carbonyl)hexanoic acid (11):  
The oxazolidine precursor of 11 was synthesized from 10a accordingly (Yield = 
71%), 
 
and characterized by NMR and MS. 1H-NMR (300 MHz, CDCl3) δ 7.38-7.26 (m, 
5H), 4.47 (s, 2H), 4.38-4.30 (m, 2H), 4.25-4.16 (m, 1H), 4.08-3.92 (m, 2H), 3.46 (m, 2H), 
2.83-2.74 (dd, J = 17.97 Hz, J = 10.68 Hz, 1H), 2.45-2.38 ( dd, J = 16.70 Hz, J = 4.11 Hz, 
1H), 1.78-1.56 ( m, 4H); ESI-MS: m/z [M+Na]+= 414.2.  
The above intermediate (13.3 g, 34 mmol) was treated with TFA (26.2 ml, 340 
mmol) in DCM (170 ml), based on a previously published procedure, to give 11 (11.3 g, 
33.7 mmol) in 99% yield. 1H-NMR (300 MHz, CDCl3) δ 7.38-7.26 (m, 5H), 4.38 (s, 2H), 
4.42-4.28 (m, 2H), 4.24-4.12 (m, 1H), 4.08-3.92 (m, 2H), 3.50 (m, 2H), 2.83-2.74 ( dd, J 
= 17.26 Hz, J = 10.18 Hz, 1H), 2.56-2.42 (dd, J = 16.70 Hz, J = 4.11 Hz, 1H), 1.78-1.56 
( m, 4H); ESI-MS: m/z [M-H]-
 
= 334.3.  
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tert-butyl 5-hydroxy-3-(2-oxooxazolidine-3-carbonyl)pentanoate (12):  
The oxazolidine precursor of 12 was synthesized from 10b accordingly (Yield = 
78%),
  
and characterized by NMR and MS. 1H-NMR (300 MHz, CDCl3) δ7.35 – 7.20 (m, 
5H), 4.50 – 4.30 (m, 2H), 4.30 – 4.20 (m, 2H), 4.17 – 3.81 (m, 2H), 3.69 – 3.52 (m, 3H), 
2.87 – 2.76 (dd, J = 16.5 Hz, J = 10.44 Hz, 1H), 2.85 – 2.76 (dd, J = 16.71 Hz, J = 
4.53Hz, 1H), 2.09 – 1.98 (m, 1H), 1.35 (s, 9H); ESI-MS: m/z [M+Na]+
 
= 414.3.  
Hydrogenolysis of above intermediate (13.2 g, 35 mmol) was accomplished in 
THF (175 ml) with Pd/C (1.32 g) by stirring the mixture at room temperature under a 
hydrogen atmosphere for 1.5 hrs. The mixture was filtered, and the filtrate concentrated 
and purified by flash chromatography (80-100% EA/hexane) to yield 12 (7.96 g, 27.7 
mmol, 79%). 1H-NMR (300 MHz, CDCl3) δ 4.43 – 4.35 (m, 2H), 4.24 – 4.14 (m, 2H), 
4.05 – 3.96 (m, 2H), 3.65 – 3.60 (t, J = 5.94 Hz, 2H), 2.83 – 2.74 (dd, J = 16.89 Hz, J = 
10.47 Hz, 1H), 2.46 – 2.39 (dd, J = 16.89 Hz, J = 4.20 Hz, 1H), 1.92 – 1.65 (m, 2H), 1.35 
(s, 9H); ESI-MS: m/z [M+Na]+
 
= 310.2.  
 
6-hydroxy-3-(2-oxooxazolidine-3-carbonyl)-N-(trityloxy)hexanamide (13):  
Coupling of acid 11 (11.4 g, 34.0 mmol) with trityl-protected hydroxylamine 
(11.2 g, 40.8 mmol) and DCC (8.42 g, 40.8 mmol) in DCM (120 ml), following 
previously published procedures,
 
yielded the corresponding intermediate (80%) after 
purification by flash chromatography (40-60% EA/hexane). 1H-NMR (300 MHz, CDCl3) 
δ 7.68 (br s, 1H), 7.38-7.26 (m, 20H), 4.45 (s, 2H), 4.38-4.22 (m, 2H), 4.04-3.82 (m, 3H), 
3.37 (m, 2H), 2.40-2.37 (m, 1H), 2.12-2.01 ( m, 1H), 1.58-1.32 (m, 4H); ESI-MS: m/z 
[M+Na]+
 
= 615.1.  
The above intermediate (16.1 g, 27.2 mmol) in THF (130 ml) and Pd/C (1.61 g) 
was stirred at room temperature under a hydrogen atmosphere for 1.5 hrs. The mixture 
was filtered, and the filtrate concentrated and purified by column chromatography (80-
100% EA/hexane) to afford 13 (10.8g, 21.5 mmol, 75%).1H-NMR (300 MHz, CDCl3) δ 
7.68 (br s, 1H), 7.38-7.26 (m, 15H), 4.47-4.34 ( m, 2H), 4.06-3.85 (m, 3H), 3.56-3.42 (m, 





2-(2-oxo-2-(trityloxyamino)ethyl)-5-(trityloxy)pentanoic acid (6I):  
To a solution of 13 (10.8 g, 21.5 mmol), DMAP (0.26 g, 2.15 mmol) and TEA 
(5.36 ml, 38.7 mmol) in DCM (240 ml) was added CPh3Cl (6.00 g, 21.5 mmol) and the 
reaction was stirred at room temperature overnight. DCM was removed in vacuo to yield 
a yellow semi-solid. Subsequently, 20% EA/hexane was added to the residue. The white 
solid obtained was filtered off and washed again with 20% EA/hexane to afford the pure 
intermediate (15.6 g, 21.0 mmol, 98%).1H-NMR (300 MHz, CDCl3) δ 7.18-7.56 (m, 
31H), 4.22 (t, J = 7.83 Hz, 2H), 3.61 (t, J = 8.73 Hz, 2H), 3.14-3.06 (q, 2H), 2.99-2.97 (m,  
1H), 2.38-2.22 (m, 1H), 1.96-1.78 (m, 1H), 1.48-1.20 (m, 4H); ESI-MS: m/z [M+Na]+= 
767.8.  
The above intermediate (15.6 g, 21.0 mmol) was treated with LiOH (1.51 g, 63.0 
mmol) and 30 % H2O2 (11.8 ml, 113 mmol) using previously published procedures,
 
followed by purification with flash chromatography (5-10% MeOH) to give 6I (9.66 g, 
14.3 mmol, 68%).1H-NMR (300 MHz, CDCl3) δ 7.25-7.16 (m, 31H), 3.18-2.82 (m, 2H), 
2.71-2.55 (m, 1H), 2.48-2.25 (m, 1H), 2.18-2.02 (m, 1H), 1.72-1.25 (m, 4H);13C-NMR 
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(75 MHz, CDCl3) δ 176.0, 174.5, 146.8, 129.2-126.4 (m), 88.9, 82.0, 68.6, 36.2, 35.4, 
24.7, 22.1; ESI-MS: m/z [M-H]-= 674.3.  
 
tert-butyl 5-oxo-3-(2-oxooxazolidine-3-carbonyl)-5-(trityloxyamino)pentanoate (14):  
            Oxidation of alcohol 12 (7.96 g, 27.7 mmol) was accomplished by following the 
procedure described for the conversion of 8a-b to 9a-b, using PDC (31.3 g, 83.1 mmol) 
in DMF (70 ml), to furnish the corresponding intermediate (6.51 g, 21.6 mmol, 78%).1H-
NMR (300 MHz, CDCl3) δ 4.48 – 4.34 (m, 3H), 4.08 – 3.93 (m, 2H), 2.84 – 2.69 (m, 2H), 
2.54 – 2.38 (m, 2H), 1.40 (br s, 9H); ESI-MS: m/z [M-H]-
 
= 300.3.  
Above intermediate (65.1 g, 21.6 mmol) was coupled with trityl-protected 
hydoxylamine (7.13 g, 25.9 mmol) and DCC (5.34 g, 25.9 mmol) in DCM (65 ml), 
following previously published procedures. Upon purification by flash chromatography 
(50-70% EA/hexane), the desired product 14 was isolated (7.37 g, 13.2 mmol, 61%).1H-
NMR (300 MHz, CDCl3) δ 7.47 – 7.32 (m, 16H), 4.37 (t, J = 8.01 Hz, 2H), 4.12 (q, J = 
7.32 Hz, 1H), 3.96 (t, J = 7.32 Hz, 2H), 2.39 – 1.85 (m, 4H), 1.40 (s, 9H); ESI-MS: m/z 
[M+Na]+
 
= 581.5.  
 
2-(2-tert-butoxy-2-oxoethyl)-4-oxo-4-(trityloxyamino)butanoic acid (6J):  
Hydrolytic cleavage of the oxazolidinone moiety in 14 (7.37 g, 13.2 mmol) was 
accomplished by LiOH (0.95 g, 39.6 mmol) and 30 % H2O2 (6.36 ml, 60.7 mmol) using 
previously published procedures, 
 
which upon purification by flash chromatography (70-
80% EA/hexane) yielded 6J (4.72 g, 9.64 mmol, 73%).1H-NMR (300 MHz, CDCl3) δ 
7.43 – 7.29 (m, 16H), 3.02-2.87 (m, 1H), 2.79-2.63 (m, 1H), 2.48-2.25 (m, 2H), 2.18-2.02 
(m, 1H), 1.43 (s, 9H);13C-NMR (75 MHz, CDCl3) δ 177.0, 172.2, 171.9, 141.8, 140.8, 
81.0, 65.0, 40.6, 36.7, 29.8, 27.9; ESI-MS: m/z [M+Na]+
 
= 512.4.  
 

































Scheme 7 Synthesis route of warhead 6K 
 
tert-butyl 6-oxo-6-(2-oxooxazolidin-3-yl)hexylcarbamate (16)  
To a solution of 6-aminohexanoic acid 15 (7.87 g, 60 mmol) and NaOH (2 M 
solution, 50ml) in dioxane/water (2:1; 180 ml) at 0 °C was added (Boc)2O (15.7 g, 72 
mmol). The reaction was allowed to proceed at room temperature overnight. 
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Subsequently, dioxane was removed under reduced pressure. The resulting mixture was 
acidified to pH 2 with 1 M HCl, then extracted with EA (3 x 80 ml). The combined 
organic extracts were dried over Na2SO4, filtered and concentrated to furnish the desired 
product as colorless oil (13.8 g, 99%), which was further reacted with 2-oxazolidinone 
(4.35 g, 50 mmol), DMAP (0.92 g, 7.5 mmol) and DCC (15.5g, 75 mmol) based on the 
general procedures described for the synthesis of 10a-b. Upon column purification (20 - 
40% EA/hexane), the desired product 16 was isolated as white solid (15.6 g, 52.0 mmol, 
65%).1H-NMR (300 MHz, CDCl3) δ 4.55 (br s, 1H), δ 4.39 (t, J = 8.01 Hz, 2H), 3.99 (t, J 
= 8.19 Hz, 2H), 3.19 – 3.02 (m, 2H), 2.89 (t, J = 7.49 Hz, 2H), 1.72 – 1.58 (m, 2H), 1.57 
– 1.35 (m, 4H), 1.41 (s, 9H); ESI-MS: m/z [M+Na]+
 
= 323.2.  
 
7-(tert-butoxycarbonyl)-3-(2-oxooxazolidine-3-carbonyl)heptanoic acid (17)  
Compound 16 (15.6 g, 52.0 mmol) was alkylated with benzyl 2-bromoacetate 
(15.5 g, 67.6 mmol) using NaHMDS (67.6 ml, 67.6 mmol) in 180 ml THF following 
previously described procedures.
 
Upon column purification (20 – 35% EA/hexane), the 
product/intermediate was isolated as colorless oil (16.6 g, 36.9 mmol, 71%).1H-NMR 
(300 MHz, CDCl3) δ 7.30 (m, 5H), δ 5.11 – 4.97 (m, 2H), 4.56 (br s, 1H), 4.42-4.28 (m, 
2H), 4.26-4.16 (m, 1H), 4.02-3.78 (m, 2H), 3.07-3.05 (m, 2H), 2.98-2.82 (dd, J = 
17.07Hz, J = 6.27Hz , 1H), 2.55-2.48 (dd, J = 16.91Hz, J = 3.84Hz , 1H), 1.65 (m, 2H), 
1.41 (m, 11H), 1.26 (m, 2H). ESI-MS; m/z [M+Na]+
 
= 437.3.  
Hydrogenolysis of the above intermediate (16.6 g, 36.9 mmol) in THF (130 ml) 
with Pd/C (1.66 g) was accomplished using procedures described earlier for the synthesis 
of 13. The desired product 17 was obtained without column purification (13.2 g, 36.9 
mmol, 99%).1H -NMR (300 MHz, CDCl3) δ 4.63 (br s, 1H), 4.39 (t, J = 8.01 Hz, 2H), 
4.18-4.10 (m, 1H), 3.98 (t, J = 8.15 Hz, 2H), 3.07-3.05 (m, 2H), 2.91-2.80 (dd, J = 
17.07Hz, J = 6.27 Hz , 1H), 2.53-2.45 (dd, J = 16.91 Hz, J = 3.84Hz , 1H), 1.68-1.63 (m, 
2H), 1.43-1.38 (m, 13H); ESI-MS: m/z [M-H]-
 
= 357.3.  
 
6-(tert-butoxycarbonyl)-2-(2-oxo-2-(trityloxyamino)ethyl)hexanoic acid (6K)  
Acid 17 (13.2 g, 36.9 mmol) was coupled with trityl-protected hydroxylamine 
(13.2 g, 48.0 mmol) and DCC (9.90 g, 48.0 mmol) in DCM (180 ml) using procedures 
previously described. Upon column purification (30 – 50% EA/hexane), the intermediate 
was obtained as a white solid (18.2 g, 29.5 mmol, 80%). 1H -NMR (300 MHz, CDCl3) δ 
7.72 (br s, 1H), 7.34 ( m, 15H), 4.52 (br s, 1H), 4.33 (t, J = 16.38Hz, 2H), 4.04-3.88 (m, 
3H), 3.04-3.052 (m, 2H), 2.40-2.30 (m, 1H), 2.08-2.02 (m, 1H), 1.48-1.26 (m, 15H); ESI-
MS: m/z [M-H]-
 
= 615.2. Hydrolysis of above intermediate was achieved by the treatment 
with LiOH (2.12 g, 88.5 mmol), H2O2 (12.4 ml, 118 mmol) in THF/H2O (3/1; 360 ml) 
using procedures previously described,
 
and purified to give the desired product 6K as a 
while solid (10.9 g, 20.0 mmol, 68%). 1H -NMR (300 MHz, CDCl3) δ 8.30 (br s, 1H), 
7.33 (m, 15H), 4.59 (br s, 1H), 3.02-2.95 (m, 2H), 2.52-2.40 (m, 1H), 2.27-2.16 (m, 1H), 
1.50-1.26 (m, 15H);13C-NMR (75 MHz, CDCl3) δ 174.9, 171.8, 146.8, 144.5, 130.0 – 
126.5 (m), 82.2, 79.6, 40.4, 36.9, 31.5, 30.5, 28.4, 23.2; ESI-MS: m/z [M+Na]+= 569.1.  
 




































































Scheme 8 Synthesis route of MMPI warhead 6L 
 
tert-butyl 2-(4-methoxyphenylthio)acetate (19):  
To a stirred solution of 18 (8.61 ml, 70 mmol) in THF (110 ml) under a nitrogen 
atmosphere at 0 ºC was added t-BuOK over 5 min. Tert-butyl bromoacetate was then 
added dropwise. The reaction mixture was stirred for another 3 hrs, after which the white 
solid formed was filtered away. The filtrate was concentrated and purified by column 
chromatography (100% hexane – 5% DCM/hexane) to furnish 19 as colorless oil (15.0 g, 
58.8 mmol, 84%).1H-NMR (300 MHz, CDCl3) δ 7.40 (d, J = 9.06 Hz, 2H), 6.82 (d, J = 
9.06 Hz, 2H), 3.76 (s, 3H), 3.41 (s, 2H), 1.38 (s, 9H); ESI-MS: m/z [M+Na]+
 
= 277.2.  
 
4-benzyl 1-tert-butyl 2-(4-methoxyphenylthio)succinate (20):  
Compound 19 (7.12 g, 28.0 mmol) was alkylated with benzyl 2-bromoacetate 
(12.8 g, 56.0 mmol) using NaHMDS (56.0 ml, 56.0 mmol) in 180 ml THF following 
general procedures described previously. 
 
Upon column purification (2 – 7% EA/hexane), 
the desired product 20 was obtained as colorless oil (8.69 g, 21.6 mmol, 77%).1H-NMR 
(300 MHz, CDCl3) δ 7.43 (d, J = 8.70 Hz, 2H), 7.34 (s, 5H), 6.84 (d, J = 8.70 Hz, 2H), 
5.12 (s, 2H), 3.79 (m, 4H), 2.94-2.85 (dd, J = 16.89 Hz, J = 9.75 Hz , 1H), 2.74-2.67 (dd, 
J =17.07 Hz, J = 5.55 Hz , 1H), 1.39 (s, 9H); ESI-MS: m/z [M+Na]+= 425.0.  
 
tert-butyl 2-(4-methoxyphenylsulfonyl)acetate (21):  
To a solution of 19 (7.12 g, 28.0 mmol) in DCM (140 ml) under a nitrogen 
atmosphere at 0 ºC was added m-CPBA (12.1 g, 70.0 mmol) in small portions. The 
reaction mixture was stirred overnight. The white solid formed was filtered away, and the 
filtrate was concentrated and purified by column chromatography (15 – 40% 
DCM/hexane), to furnish 21 (5.61 g, 19.6 mmol, 70%).1H-NMR (300 MHz, CDCl3) δ 
7.79 (d, J = 8.71 Hz, 2H), 7.00 (d, J = 8.72 Hz, 2H), 3.99 (s, 2H), 3.87 (s, 3H), 1.37 (s, 
9H); ESI-MS: m/z [M+Na]+= 308.9.  
 
4-benzyl 1-tert-butyl 2-(4-methoxyphenylsulfonyl)succinate (22):  
            Compound 20 (8.69 g, 21.6 mmol) was oxidized with m-CPBA (9.32 g, 54.0 mol) 
using procedures described for the conversion of 19 to 21. Upon column purification (60 
48 
– 80% EA/hexane), the desired product 22 was isolated as colorless oil (7.13 g, 16.4 
mmol, 76%)  
Sulfone 21 (5.61 g, 19.6 mmol) was alkylated with benzyl 2-bromoacetate (8.98 g, 
39.2 mmol) using NaHMDS (39.2 ml, 39.2 mmol) in 100 ml THF following procedures 
described earlier. Upon column purification (60-80% EA/hexane), the desired product 22 
was isolated (6.39 g, 14.7 mmol, 75%).1H-NMR (300 MHz, CDCl3) δ 7.79 (d, J = 9.06 
Hz, 2H), 7.34 (s, 5H), 7.01 (d, J = 9.06 Hz, 2H), 5.11 (s, 2H), 4.33 (t, J = 14.97Hz, 1H), 
3.88 (s, 3H), 3.10 (d, J = 7.32 Hz, 2H), 1.34 (s, 9H); ESI-MS: m/z [M+Na]+
 
= 457.0.  
 
4-(benzyloxy)-2-(4-methoxyphenylsulfonyl)-4-oxobutanoic acid (23):  
Cleavage of the tert-butyl group in 22 (13.0 g, 30 mmol) with TFA (23.1 ml, 300 
mmol) in DCM (150 ml) was accomplished using procedures described previously
 
to 
give 23 (11.1 g, 29.4 mmol, 98%).1H-NMR (300 MHz, CDCl3) δ 7.78 (d, J = 8.73 Hz, 
2H), 7.33 (s, 5H), 7.01 (d, J = 8.73 Hz, 2H), 5.64 (br s, 1H), 5.10 (q, 2H), 4.46 (t, J = 
14.61 Hz, 1H), 3.87 (s, 3H), 3.11 (d, J = 7.68 Hz, 2H); ESI-MS: m/z [M+Na]+
 
= 401.1.  
 
1-(9H-fluoren-9-yl)methyl 4-benzyl 2-(4-methoxyphenylsulfonyl)succinate (24):  
Acid 23 (11.1 g, 29.4 mmol) was coupled with Fmoc-OH (4.35 g, 29.4 mmol), 
using DCC (7.28 g, 35.3 mmol) and DMAP (0.43 g, 3.53 mmol) following procedures 
described previously. Upon column purification (10 - 25% EA/hexane), the desired 
product 24 was isolated (15.5 g, 27.9 mmol, 95%).1H-NMR (300 MHz, CDCl3) δ 7.77 (q, 
4H), 7.60 (d, J = 7.28 Hz, 2H), 7.52 (d, J = 7.28 Hz, 2H), 7.42 ( t, J = 12.28 Hz, 2H), 
7.30 (m, 7H), 6.96 (d, J = 8.73 Hz, 2H), 5.11 (q, 2H), 4.56 (t, J = 14.97 Hz, 1H), 4.38 (q, 
1H), 4.23 (q, 1H), 4.10 (q, 1H), 3.81 (s, 3H), 3.19 (d, J = 7.32 Hz, 2H); ESI-MS: m/z 
[M+Na]+= 579.2.  
 
4-((9H-fluoren-9-yl)methoxy)-3-(4-methoxyphenylsulfonyl)-4-oxobutanoic acid (25):            
Hydrogenolysis of 24 (15.5 g, 27.9 mmol) in THF (140 ml) with Pd/C (1.55 g) was 
accomplished using procedures described for the synthesis of 13. Upon column 
purification (5-10% DCM/hexane), the desired product 25 was isolated (12.2 g, 26.2 
mmol, 94%).1H-NMR (300 MHz, CDCl3) δ 7.78 (q, 4H), 7.60 (d, J = 7.28 Hz, 1H), 7.52 
(d, J = 7.28 Hz, 1H), 7.42 (t, J = 12.28 Hz, 2H), 7.30 (m, 2H), 6.96 (d, J = 8.73 Hz, 2H), 
4.50 (m, 2H), 4.25 (t, J = 17.76 Hz, 1H), 3.81 (s, 3H), 3.15 (d, 1H), 3.81 (s, J = 9.09 Hz, 
2H); ESI-MS: m/z [M+Na]+
 
= 489.1.  
 
(9H-fluoren-9-yl)methyl 2-(4-methoxyphenylsulfonyl)-4-(trityloxyamino)butanoate (26):  
Acid 25 (12.2 g, 26.2 mmol) was coupled with trityl-protected hydroxylamine 
(8.65 g, 31.4 mmol) and DCC (6.48 g, 31.4 mmol) in DCM (130 ml) using procedure 
described previously. After column purification (20 – 30% EA/hexane), 26 (13.8 g, 19.1 
mmol, 73%) was isolated as a white solid.1H-NMR (300 MHz, CDCl3) δ 7.78 (q, 4H), 
7.60 (d, J = 7.28 Hz, 1H), 7.52 (d, J = 7.28 Hz, 1H), 7.35 (m, 20H), 6.93 (d, J = 9.06 Hz, 
2H), 4.48-4.35 (m, 1H), 4.30-4.08 ( m, 3H), 3.83 (s, 3H), 2.50 (m, 1H), 2.08 (m, 1H); 
ESI-MS: m/z [M+Na]+
 
= 746.2.  
 
2-(4-methoxyphenylsulfonyl)-4-oxo-4-(trityloxyamino)butanoic acid (6L):  
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26 (13.8 g, 19.1 mmol) was stirred in 20% piperidine (in DMF; 100ml) at room 
temperature for 15 min. The reaction mixture was concentrated in vacuo and purified by 
column chromatography (5-10% MeOH/DCM) to furnish 6L as an off-white solid (10.1 
g, 18.5 mmol, 97%).1H-NMR (300 MHz, CDCl3) δ 7.72 (d, J = 8.34 Hz, 2H), 7.35-7.24 
(m, 16H), 4.10-4.02 (m, 1H), 3.87 (s, 3H), 2.58-2.49 (m, 1H), 2.47-2.32 (m, 1H);13C-
NMR (75 MHz, CDCl3) δ 164.2, 146.8, 140.6, 131.4, 129.0 – 127.5 (m), 114.3, 65.7, 
55.7, 45.8, 29.7. ESI-MS: m/z [M+Na]+
 
= 568.2.  
 
5.4 Solid phase synthesis of 400 member library containing 20 amino acids in the 
P2’ and P3’ positions  
 
The construction of the 400-members MMP inhibitors library was achieved by 
standard Fmoc solid phase peptide synthesis, IRORI split-and-pool directed sorting 
technology (Scheme 5. 3).
 
The synthesis involved the use of only 20 reaction bottles in 
three rounds of synthesis and sorting. Final products were released from the solid phase 
by standard TFA cleavage protocol. The average concentration of individual inhibitors in 
DMSO stock solution was adjusted to a uniform 230 μM (estimated using ACC dye 






































































































































Scheme 9 Procedure for the synthesis of 400-member MMP inhibitors on solid-phase.  
Reagents and conditions: (a) i: Fmoc-Lys(Biotin)-OH, HOBt, HBTU, DIEA, 12 hrs; ii: 
20% piperidine/DMF, 2 hrs (b) i: Fmoc-Gly-OH, HOBt, HBTU, DIEA, 6 hrs; ii: 20% 
piperidine/DMF, 2 hrs (c) i: Fmoc-Gly-OH, HOBt, HBTU, DIEA, 6 hrs; ii: 20% 
piperidine/DMF, 2 hrs (d) i: Fmoc-AA
3
-OH, HOBt, HBTU, DIEA, 8 hrs; ii: 20% 
piperidine/DMF, 2 hrs (e) i: Fmoc-AA
2
-OH, HOBt, HBTU, DIEA, 8 hrs; ii: 20% 
piperidine/DMF, 2 hrs (f) i: CPh
3
ONH-Suc(2-iBu)-OH, HOBt, HBTU, DIEA, 12 hrs; ii: 
20% piperidine/DMF, 2 hrs (g) 95% TFA/ 5% TIS, 2 hrs  
 
 






































Scheme 10 Synthesis route of Fmoc-Lys(Biotin)-OH 
 
Biotin-NHS. To a solution of D-biotin (24 g, 100 mmol) in DMF was added N-
hydroxysuccinimide (14 g, 120 mmol) and EDC (23 g, 120 mmol). The reaction was 
allowed to proceed overnight. The resulting mixture was dried in vacuo to remove DMF. 
The gel-like residue was recrystallized from EtOH/Acetic acid/H2O(95:1:4) to afford 
biotin-NHS as a white solid (29 g; 85% yield):1H-NMR (300 MHz, CD3OD) δ 6.40 (br s, 
1H), 6.35 (br s, 1H), 4.33-4.29 (m, 1H), 4.17-4.13 (m, 1H), 3.12-3.08 (m, 1H), 2.86-2.81 
(m, 5H) including 2.81 (s, 4H), 2.67 (t, J = 7.2 Hz, 2H),  2.61-2.59 (m, 1H), 1.70-1.24 (m, 
6H); ESI-MS cald for C14H20N3O5S [M+H]+
 
342.1, found 342.1.  
 
Fmoc-Lys(Biotin)-OH. To a solution of Fmoc-Lys(Boc)-OH (39.8 g, 85 mmol) in DCM 
(0.4 ml) was added TFA (80 ml). The reaction was stirred at room temperature for 1 hour 
and concentrated in vacuo. The oil residue was dissolved in 280 ml of 1:1 Dioxane/water 
co-solvent, and the pH of the solution was adjusted to 8~8.5 by using a 4 M NaOH 
solution at 0oC. Biotin-NHS (29 g, 85 mmol) and was subsequently added, and the 
reaction mixture was stirred at room temperature overnight. The resulting gelatinous solid 
formed was added ether, stirred for 5 minutes. The supernatant ether was decanted 
followed by addition of acetone and adjusting the pH of the resulting solution to 3 using 2 
M HCl at 0oC. Finally, the solid was filtered, washed several times with MeOH to afford 
the pure Fmoc-K(Biotin)-OH as a white solid (41.5 g, 82%):1H-NMR (300 MHz, 
CD3OD) δ 7.89 (d, J = 7.6 Hz, 2H), 7.72 (d, J = 7.7 Hz, 2H), 7.42 (t, J = 7.3 Hz, 2H), 
7.33 (t, J = 7.3 Hz, 2H), 6.41 (br s, 1H), 6.35 (br s, 1H), 4.31-4.22 (m, 4H), 4.13-4.09 (m, 
1H), 3.91-3.84 (m, 1H), 3.10.-3.00 (m, 3H), 2.80 (dd, J = 4.9 Hz, J = 12.2 Hz, 1H), 2.56 
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(d, J = 12.5 Hz, 1H), 2.03 (t, J = 7.3 Hz, 2H), 1.61-1.29 (m, 12H); ESI-MS cald for 
C31H39N4O6S [M+H]+
 
595.3, found 595.2.  
 
5.4.2 Experimental details of the solid phase synthesis  
Synthesis of Fmoc-Lys (biotin)-OH resin. To a 1-litre glass bottle was added a solution 
of 20% piperidine in DMF and 12 g of Rink Amide AM resin (loading: 0.5 mmol/g). The 
mixture was shaken for 2 hours. The resin was filtered and washed with DMF (3 x), 
DCM (3 x) and DMF (3 x). The preactivated solution containing Fmoc-Lys(biotin)-OH 
(4.0 eq), HOBt (4.0 eq), DIC (4.0 eq), DIEA (4.0 eq) in DMF (400 ml) was added. The 
reaction was shaken overnight at room temperature. The resin was then washed with 
DMF (3 x), DCM (3 x) and DMF (3 x). Subsequently, Fmoc was removed following 20% 
piperidine treatment as described below.  
Loading GG linker. To a 1-litre bottle was added biotin-linked resin and a preactivated 
solution of Fmoc-Gly-OH (4.0 eq), HOBt (4.0 eq), HBTU (4.0 eq) and DIEA (8.0 eq) in 
500 ml DMF. The reaction mixture was shaken for 6 hours and the resin was then washed 
with DMF, DCM, and DMF. Subsequently, Fmoc was deprotected by 20% piperidine in 
DMF for 2 hours. The procedures were repeated to load the second Fmoc-Gly-OH 
coupling.  
Loading of P2’, P3’
 
residues. To a 1-litre glass bottle was added a solution of 20% 
piperidine in DMF and 400 microreactors (each containing 30 mg of Lysin(biotin)-GG-
Fmoc resin and an Rf tag). The mixture was shaken for 2 hours and then the 
microreactors were washed with DMF (3 x), DCM (3 x) and DMF (3 x). The 
microreactors were then distributed into twenty bottles and each bottle was subjected to a 
solution of a unique Fmoc-protected amino acid (4.0 eq), and HOBt (4.0 eq), HBTU (4.0 
eq) and DIEA (8.0 eq) in DMF (50 ml). After shaken for 8 hours, the microreactors were 
washed with DMF (3 x 400 ml), DCM (3 x 400 ml) and DMF (3 x 400 ml). The Fmoc 
group was then deprotected by 20% piperidine, and the microreactors were washed with 
DMF. To load the residue of P
2
’
, repeat the above procedure.  
Loading P1’ residue: succinic acid derivative (w/ 1% Fmoc-ACC). The 400 
microreactors were added a preactived solution of succinic acid derivative (4.0 eq), 
Fmoc-ACC (0.04 eq), HOBt (4.0 eq), HBTU (4.0 eq) and DIEA (8.0 eq) in DMF. The 
reaction mixture was shaken overnight and then the microreactors were washed with 
DMF, DCM and DMF. The Fmoc group was removed and the microreactors were 
washed with DMF, MeOH and dried under vacuum.  
Cleavage from the solid support. Each dried microreactor was treated with an 1-ml 
solution containing TFA (95%), TIS (5%) and the mixture was shaken for 4 hours at rt. 
The cleavage solution was then transferred to 96-well plates and then concentrated in 
vacuo.  
Precipitation. To each vessel was added ether and the plate was kept in a -20oC freezer 
overnight. Removal of the ether layer after centrifugation for 10 minutes gave 400 
peptide products. Then each peptide was dissolved in DMSO (0.5 ml).  
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Quantification. The final coupling step incorporated 1% coumarin to each of the small 
molecule inhibitors in order to facilitate a fluorescence-based approach for concentration 
determination. 10 μl of the peptide solutions were diluted into PBS buffer (pH 7.4) to a 
final volume of 200 μl. The solutions were transfer to 96-well microtitre plates scanned 
for fluorescence under the coumarin channel λex= 360 nm and λem = 455 nm using a 
SpectraMAX
TM 
Gemini XS fluorescence plate reader (Molecular Devices, USA). A 
linear concentation gradient was also using unconjugated aminomethylcarboxycoumarin 
(ACC) and this standard was used to estimate concentrations of each library member.  
 
5.4.3 Library characterization 
The purity of the final products was determined by Shimadzu automated RP-HPLC, 
with single major peaks obtained in most cases (214 nm). ESI-MS spectrometry was 
taken for selected samples to further confirm successful synthesis (Figure 5.3.3). Six 













P2' - P3' IC50 
(nM) 




Leu-Phe 144.5 NDa 916.5 
(917.1) 
Ser-Ser 176.7 104 830.2 
(830.9) 
Ser-Tyr 107.3 ND 906.2 
(907.0) 
Tyr-Gln 38.5 ND 947.3 
(948.1) 
Tyr-Asn 33.1 ND 933.3 
(934.1) 
Tyr-Lys 9.9 2.4 947.3 
(948.1) 
GM6001 23.9 25.2 - 
                                  aND = Not determined 
 
Table 2 Ki/IC50 values of 6 selected inhibitors from the library together with commercial 
inhibitor GM6001 is tabulated together with results obtained from large-scale microarray 
and microplate screens. ESI-MS results are also displayed.  
 
5.5 Solid phase synthesis of 1000 member library containing 10 amino acids in the 
P2’ and P3’ positions and 10 variations in the P1’ position 
         The construction of 1000 member MMPI library was done by following the 
protocol as described in section 5.3, except minor change made in the final coupling step. 
Instead of using HOBt/HBTU/DIEA as coupling reagent, HATU/DIEA had been used to 





































































































































































































Scheme 11 Procedure for the synthesis of 400-member MMP inhibitors on solid-phase.  
Reagents and conditions: (a) i: Fmoc-Lys(Biotin)-OH, HOBt, HBTU, DIEA, 12 hrs; ii: 
20% piperidine/DMF, 2 hrs (b) i: Fmoc-Gly-OH, HOBt, HBTU, DIEA, 6 hrs; ii: 20% 
piperidine/DMF, 2 hrs (c) i: Fmoc-Gly-OH, HOBt, HBTU, DIEA, 6 hrs; ii: 20% 
piperidine/DMF, 2 hrs (d) i: Fmoc-AA3-OH, HOBt, HBTU, DIEA, 8 hrs; ii: 20% 
piperidine/DMF, 2 hrs (e) i: Fmoc-AA2-OH, HOBt, HBTU, DIEA, 8 hrs; ii: 20% 
piperidine/DMF, 2 hrs (f) i: CPh3ONH-Suc(2-P1’)-OH, HATU, DIEA, 12 hrs; ii: 20% 
piperidine/DMF, 2 hrs (g) 95% TFA/ 5% TIS, 2 hrs  
  
5.6 Rapid assembly of metalloprotease inhibitor using click chemistry 
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Scheme 12 Synthesis route of alkyne building block 
 
General procedure for the coupling of 6A-6H with propargyl amine:  
 
         To a solution of 6 (A to H) (5 mmol), HATU (6 mmol) and DIEA (6 mmol) in 
DMF (10 ml) was added propargyl amine (6 mmol) at room temperature under a nitrogen 
atmosphere. The mixture was stirred for 2-4 hrs. The solvent was removed in vacuo and 
the resulting oil residue was diluted with DCM and extracted with water. The combined 
DCM layers were dried over Na2SO4, filtered and concentrated. The crude product was 
purified by column chromatography (80% DCM/hexane – 10% MeOH/DCM) to afford 
27 (A to H) in 80 – 91% yield, typically as a white or off-white solid.  
 
2-isopropyl-N1-(prop-2-ynyl)-N4-(trityloxy)succinamide (27A):  
Yield = 88%.1H-NMR (300 MHz, DMSO-d6) δ 7.39 – 7.18 (m, 15H), 3.89 – 3.63 
(m, 2H), 2.50 (s, 1H), 2.38 – 1.72 (m, 3H), 1.53 – 1.43 (m, 1H), 0.63 – 0.49 (m, 6H); 
ESI-MS: m/z [M+Na]+ = 477.3. 
  
2-isobutyl-N1-(prop-2-ynyl)-N4-(trityloxy)succinamide (27B):  
Yield = 80%.1H-NMR (300 MHz, CDCl3) δ 7.43 – 7.38 (m, 15H), 3.85 – 3.69 (m, 
2H), 2.80 (s, 1H), 2.45 – 2.31 (m, 1H), 2.23 – 2.08 (m, 2H), 1.42 – 1.28 (m, 3H), 0.84 – 
0.68 (m, 6H); ESI-MS: m/z [M+Na]+ = 491.6. 
  
2-sec-butyl-N1-(prop-2-ynyl)-N4-(trityloxy)succinamide (27C):  
            Yield = 91%. 1H-NMR (300 MHz, CDCl3) δ 7.44 – 7.26 (m, 15H), 3.94 – 3.78 (m, 
2H), 2.50 – 2.34 (m, 1H), 2.28 – 2.13 (m, 2H), 1.70 (s, 1H), 1.35 – 1.19 (m, 3H), 0.85 – 
0.69 (m, 6H); ESI-MS: m/z [M+Na]+ = 491.5. 
  
2-benzyl-N1-(prop-2-ynyl)-N4-(trityloxy)succinamide (27D):  
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Yield = 82%. 1H-NMR (300 MHz, CDCl3) δ 7.65 – 6.93 (m, 20H), 4.02 – 3.57 (m, 
2H), 2.80 (s, 1H), 2.68 – 2.30 (m, 3H), 2.26 – 2.11 (m, 2H); ESI-MS: m/z [M+Na]+ = 
525.4.  
 
2-(3-phenylpropyl)-N1-(prop-2-ynyl)-N4-(trityloxy)succinamide (27E):  
Yield = 82%.1H-NMR (300 MHz, CDCl3) δ 7.45 – 6.99 (m, 20H), 3.90 – 3.73 (m, 
2H), 2.79 (s, 1H), 2.52 – 2.36 (m, 5H), 1.49 – 1.32 (m, 4H); ESI-MS: m/z [M+Na]+ = 
553.6.  
 
2-cyclohexyl-N1-(prop-2-ynyl)-N4-(trityloxy)succinamide (27F):  
Yield = 83%. 1H-NMR (300 MHz, MeOD) δ 7.48 – 7.22 (m, 15H), 4.06 – 3.81 
(m, 2H), 2.81 (s, 1H), 2.57 – 2.54 (m, 1H), 2.30 – 2.15 (m, 2H), 1.69 – 0.89 (m, 11H); 
ESI-MS: m/z [M+Na]+ = 517.4. 
  
2-(cyclopentylmethyl)-N1-(prop-2-ynyl)-N4-(trityloxy)succinamide (27G):  
Yield = 85%.1H-NMR (300 MHz, CDCl3) δ 7.48 – 7.26 (m, 15H), 4.03 – 3.81 (m, 
2H), 2.41 – 2.38 (m, 2H), 2.19 – 2.16 (m, 2H), 1.63 – 1.26 (m, 8H), 1.09 – 0.88 (m, 3H); 
ESI-MS: m/z [M+Na]+= 517.5. 
  
2-(2-(benzyloxy)ethyl)-N1-(prop-2-ynyl)-N4-(trityloxy)succinamide (27H):  
Yield = 80%. 1H-NMR (300 MHz, CDCl3) δ 7.44 – 7.20 (m, 20H), 4.48 – 4.39 (m, 
1H), 4.35 – 4.21 (m, 1H), 4.02 – 3.62 (m, 2H), 3.48 – 3.22 (m, 2H), 2.75-2.52 (m, 1H), 
2.48-2.22 (m, 1H), 2.20 (s, 1H), 1.95-1.80 (m, 1H), 1.73-1.51 (m, 3H); ESI-MS: m/z 
[M+23]+ = 569.4.  
 
General procedure for the cleavage of trityl moiety in AlkyneA-AlkyneH  
 
         To a solution of 27 (4 mmol) in DCM (8 ml) was added TFA (40 mmol) and TIS (8 
μl). The mixture was stirred for 1 hr, following which the solvent was removed in vacuo. 
The crude product was purified by column chromatography (5% MeOH/DCM–10% 
MeOH/DCM). AlkyneA-AlkyneH was isolated in 40 – 55% yield.  
 
N4-hydroxy-2-isopropyl-N1-(prop-2-ynyl)succinamide (AlkyneA):  
Yield = 52%.1H-NMR (300 MHz, MeOD) δ 4.08 – 4.00 (m, 1H), 3.90 – 3.83 (m, 
1H), 2.65 – 2.56 (m, 1H), 2.56 – 2.46 (m, 1H), 2.45 – 2.36 (m, 1H), 2.34 – 2.26 (m, 1H), 
1.87 – 1.83 (m, 1H), 1.04 – 0.94 (m, 6H);13C-NMR (75 MHz, CDCl3) δ 177.2, 172.2, 
81.3, 72.9, 37.3, 34.3, 32.9, 30.1, 21.5; HRMS cald for C10H16O3N2Na [M + Na]+
 
: 
235.1053, found 235.1057.  
 
N4-hydroxy-2-isobutyl-N1-(prop-2-ynyl)succinamide (AlkyneB):  
Yield = 43%. 1H-NMR (800 MHz, MeOD) δ 4.06 – 3.96 (m, 1H), 3.93 – 3.87 (m, 
1H), 2.86 – 2.76 (m, 1H), 2.64 – 2.53 (m, 1H), 2.39 – 2.29 (m, 1H), 2.23 – 2.13 (m, 1H), 
1.61 – 1.56 (m, 2H), 1.26 – 1.16 (m, 1H), 0.98 – 0.89 (m, 6H); 13C-NMR (75 MHz, 
CDCl3) δ 177.9, 171.5, 81.3, 73.0, 43.4, 40.3, 30.3, 27.8, 24.4, 23.2; HRMS cald for 
C11H18O3N2Na [M + Na]+: 249.1220, found 249.1215.  
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2-sec-butyl-N4-hydroxy-N1-(prop-2-ynyl)succinamide (AlkyneC):  
Yield = 45%. 1H-NMR (800 MHz, MeOD) δ 4.07 – 3.98 (m, 1H), 3.97 – 3.82 (m, 
1H), 2.72 – 2.62 (m, 1H), 2.61 – 2.53 (m, 1H), 2.45 – 2.35 (m, 1H), 2.31 – 2.21 (m, 1H), 
1.71 – 1.61 (m, 1H), 1.52 – 1.43 (m, 1H), 1.24 – 1.14 (m, 1H), 0.99 – 0.89 (m, 6H); 13C-
NMR (75 MHz, CDCl3) δ 177.4, 172.4, 81.5, 72.9, 39.4, 36.4, 34.4, 30.2, 28.9, 17.0, 
12.3; HRMS cald for C11H18O3N2Na [M + Na]+
 
: 249.1220, found 249.1221.  
 
2-benzyl-N4-hydroxy-N1-(prop-2-ynyl)succinamide (AlkyneD):  
Yield = 48%. 1H-NMR (800 MHz, MeOD) δ 7.39 – 7.11 (m, 5H), 3.97 – 3.82 (m, 
2H), 3.01 – 2.99 (m, 1H), 2.99 – 2.86 (m, 1H), 2.74 – 2.72 (m, 1H), 2.59 – 2.53 (m, 1H),  
2.43 – 2.35 (m, 1H), 2.23 – 2.20 (m, 1H); 13C-NMR (75 MHz, CDCl3) δ 176.8, 
171.5, 140.9, 131.0, 130.3, 128.4, 81.0, 73.0, 46.8, 40.3, 36.6, 30.2; HRMS cald for 
C14H16O3N2Na [M + Na]+
 
283.1053, found 283.1061.  
 
N4-hydroxy-2-(3-phenylpropyl)-N1-(prop-2-ynyl)succinamide (AlkyneE):  
          Yield = 41%. 1H-NMR (800 MHz, MeOD) δ 7.37 – 7.18 (m, 5H), 4.06 – 4.04 (m, 
1H), 3.98 – 3.82 (m, 1H), 2.76 – 2.63 (m, 1H), 2.61 – 2.60 (m, 1H), 2.59 (s, 1H), 2.49 – 
2.47, 2.19 – 2.16 (m, 1H), 2.40 – 2.31 (m, 1H), 1.66 – 1.51 (m, 3H), 1.50 – 1.47 (m, 1H); 
13C-NMR (75 MHz, CDCl3) δ 177.6, 171.6, 144.2, 130.2, 127.6, 81.4, 73.0, 42.0, 40.0, 
37.5, 33.7, 31.0, 30.3; HRMS cald for C16H19O3N2 [M-1]
- : 287.1390, found 287.1389.  
 
2-cyclohexyl-N4-hydroxy-N1-(prop-2-ynyl)succinamide (AlkyneF):  
Yield = 48%. 1H-NMR (800 MHz, MeOD) δ 4.08 – 3.97 (m, 1H), 3.86 – 3.80 (m, 
1H), 2.56 (br s, 1H), 2.56 – 2.38 (m, 2H), 2.35 – 2.27 (m, 1H), 1.77 – 1.73 (m, 3H), 1.69 
– 1.49 (m, 2H), 1.54 – 1.44 (m, 1H), 1.30 – 1.21 (m, 2H), 1.20 – 1.11 (m, 1H), 1.09 – 
0.91 (m, 2H); 13C-NMR (75 MHz, CDCl3) δ 177.2, 172.2, 81.4, 72.9, 42.6, 37.2, 34.4, 
32.6, 30.5, 28.3; HRMS cald for C13H20O3N2Na [M + Na]+
 
: 275.1366, found 275.1371.  
 
2-(cyclopentylmethyl)-N4-hydroxy-N1-(prop-2-ynyl)succinamide (AlkyneG):  
Yield = 55%. 1H-NMR (800 MHz, MeOD) δ 4.03 – 4.01 (dd, J = 17.6 Hz, J = 2.4 
Hz, 1H), 3.97 – 3.84 (m, 1H), 2.77 – 2.70, 2.59 – 2.56 (m, 1H), 2.56 (s, 1H), 2.44 – 2.42, 
2.18 – 2.15 (m, 1H), 2.32 – 2.28 (m, 1H), 1.86 – 1.84 (m, 1H), 1.77 – 1.74 (m, 2H), 1.71 
– 1.63 (m, 1H), 1.62 – 1.61 (m, 2H), 1.54 – 1.51 (m, 2H), 1.35 – 1.32 (m, 1H), 1.12 – 
1.07 (m, 2H); 13C-NMR (75 MHz, CDCl3) δ 177.9, 174.1, 81.4, 72.9, 41.5, 40.4, 40.0, 
34.9, 34.1, 30.3, 26.9; HRMS cald for C13H20O3N2Na [M + Na]+
 
: 275.1366, found 
275.1362.  
 
2-(2-(benzyloxy)ethyl)-N4-hydroxy-N1-(prop-2-ynyl)succinamide (AlkyneH):  
         Yield = 52%. 1H-NMR (300 MHz, MeOD) δ 7.40 – 7.23 (m, 5H), 4.46 (s, 2H), 3.92 
– 3.74 (m, 2H), 3.48 (br s, 1H), 3.02 – 2.84 (m, 1H), 2.57 (s, 1H), 2.40 – 2.25 (m, 2H), 
1.38 – 1.30 (m, 2H); 13C-NMR (75 MHz, CDCl3) δ 177.3, 171.5, 140.5, 130.2, 129.8, 
129.5, 81.4, 74.9, 73.2, 69.6, 41.9, 34.5, 30.4, 26.9; HRMS cald for C16H20O4N2Na [M + 
Na]+
 





Characterizations of Side Reaction during TFA deprotection of warheads: 
 
    A prominent side product was consistently observed in the last TFA cleavage step. 
Three of these side products were isolated, further characterized by NMR and confirmed 
to be the cyclic adducts, SP1, SP2 & SP3 (Figure 5.5). They are presumably generated 
from the acid-catalyzed cyclization reaction of the warheads as proposed in Figure 2. 



























Scheme 13 Side reaction in the last TFA cleavage step 
 
3-cyclohexyl-1-hydroxypyrrolidine-2,5-dione (SP1):  
1H-NMR (300 MHz, CDCl3) δ 2.79-2.72 (m, 1H), 2.71-2.63 (m, 2H), 2.51-2.44 (dd, 
J=17.33 Hz, 3.20Hz, 1H), 1.97-1.85 (m, 1H), 1.83-1.62 (m, 4H), 1.55-1.45 (m, 1H), 1.35-
1.02 (m, 5H);  
 
3-benzyl-1-hydroxypyrrolidine-2,5-dione (SP2):  
1H-NMR (300 MHz, CDCl3) δ 7.33 – 7.21 (m, 3H), 7.17 – 7.15 (m, 2H), 3.26-3.18 (m, 
1H), 3.17-3.10 (m, 1H), 2.87 – 2.79 (m, 1H), 2.71-2.62 (dd, J= 18.15 Hz, 8.46 Hz, 1H), 
2.70 (s, 1H), 2.46-2.38 (dd, J= 18.17 Hz, 4.04Hz, 1H).  
 
1-hydroxy-3-(3-phenylpropyl)pyrrolidine-2,5-dione (SP3):  
1H-NMR (300 MHz, CDCl3) δ 7.29-7.24 (m, 2H), 7.19-7.14 (m, 3H), 2.80-2.75 (m, 2H), 
2.66-2.60 (m, 3H), 2.32-2.22 (m, 1H), 1.92-1.88 (m, 1H), 1.75-1.63 (m, 2H), 1.61-1.48 
(m, 1H).  
 
Azide (Azide1 -Azide12) Synthesis  
 
           Azide1-Azide7 were synthesized from the corresponding acid chlorides and 





Azide4 Azide5 Azide6 Azide7











































































Scheme 14 Structure and synthesis of 12 Azide-containing blocks 
 
3-azido-N-(9H-fluoren-2-yl)propanamide (Azide1):  
          Yield = 69%. 1H-NMR (300 MHz, CDCl3) δ 7.86 (br s, 1H), 7.70 (t, J = 7.40 Hz, 
2H), 7.53 – 7.49 (m, 1H), 7.35 – 7.26 (m, 4H), 3.86 (s, 2H), 3.73 (t, J = 6.24 Hz, 2H), 
2.61 (t, J = 6.33 Hz, 2H); ESI-MS: m/z [M+Na]+ = 301.3.  
 
4-azido-N-(9H-fluoren-2-yl)butanamide (Azide2):  
          Yield = 82%. 1H-NMR (300 MHz, CDCl3) δ 7.87 (br s, 1H), 7.73 – 7.68 (t, J = 
6.72 Hz, 2H), 7.51 (d, J = 7.23 Hz, 1H), 7.38 – 7.25 (m, 4H), 3.87 (s, 2H), 3.44 (t, J = 
6.42 Hz, 2H), 2.49 (t, J = 7.08 Hz, 2H), 2.06-2.01 (m, 2H); ESI-MS: m/z [M+Na]+ = 
315.3.  
 
5-azido-N-(9H-fluoren-2-yl)pentanamide (Azide3):  
           Yield = 73%. 1H-NMR (300 MHz, CDCl3) δ 7.87 (br s, 1H), 7.73 – 7.68 (t, J = 
7.23 Hz, 2H), 7.51 (d, J = 7.23 Hz, 1H), 7.38 – 7.27 (m, 4H), 3.87 (s, 2H), 3.34 (t, J = 
6.59 Hz, 2H), 2.42 (t, J = 7.23 Hz), 1.89 – 1.80 (m, 2H), 1.75 – 1.68 (m, 2H); ESI-MS: 
m/z [M+23]+ = 329.3.  
 
methyl 2-(3-azidopropanamido)-3-(1H-indol-3-yl)propanoate (Azide4):  
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             Yield = 75%. 1H-NMR (300 MHz, CDCl3) δ 8.27 (br s, 1H), 7.52 (d, J = 7.71 Hz, 
1H), 7.34 (d, J = 7.74 Hz), 7.25 – 7.09 (m, 2H), 6.98 (s, 1H), 6.18 (br d, 1H), 4.99- 4.93 
(m, 1H), 3.70 (s, 3H), 3.61 – 3.51 (m, 2H), 3.33 (t, J = 3.30 Hz, 2H), 2.37 – 2.32 (m, 2H); 
ESI-MS: m/z [M+1]+ = 316.3.  
 
methyl 2-(4-azidobutanamido)-3-(1H-indol-3-yl)propanoate (Azide5):  
             Yield = 72%. 1H-NMR (300 MHz, CDCl3) δ 8.25 (br s, 1H), 7.53 (d, J=7.74 Hz, 
1H), 7.36 (d, J=7.89 Hz, 1H), 7.23-7.10 (m, 2H), 6.97 (d, J=2.31 Hz, 1H), 4.98 – 4.92 (m, 
1H), 3.71 (s, 3H), 3.32 (t, J = 5.51 Hz, 2H), 3.26 (t, J = 6.66 Hz, 2H), 2.21 (t, J = 7.23 Hz, 
2H), 1.86 (quintet, J = 6.90 Hz); ESI-MS: m/z [M+1]+ = 330.1.  
 
methyl 2-(4-azidobutanamido)-3-(4-hydroxyphenyl)propanoate (Azide6):  
             Yield = 75%. 1H-NMR (300 MHz, CDCl3) δ 6.96 – 6.93 (m, 2H), 6.76 – 6.71 (m, 
2H), 6.06 (br s, 1H), 4.90 – 4.83 (m, 1H), 3.75 (s, 2H), 3.30 – 3.25 (m, 2H), 3.13 – 2.94 
(m, 2H), 2.27 (t, J = 7.41 Hz, 2H), 1.87 (quintet, J = 6.86 Hz, 2H); ESI-MS: m/z [M+23]+ 
= 329.1.  
 
N-(4-fluorobenzyl)-3-azidopropanamide (Azide7):  
            Yield = 75%.1H-NMR (300 MHz, CDCl3) δ 7.25 – 7.20 (m, 2H), 7.02 – 6.97 (t, J 
= 8.63 Hz, 2H), 6.39 (br s, 1H), 4.37 (d, J = 5.91 Hz, 2H), 3.60 (t, J = 6.41 Hz, 2H), 2.43 
(t, J = 6.33 Hz, 2H); ESI-MS: m/z [M-1]- = 221.5.  
 

































96 member MMPI  
 
Scheme 15 Assembling of MMPI library using “Click Chemistry” 
 
The 96-membered library of MMP inhibitors were assembled in situ in a 96-deep 
well microplate. Both the alkynes (5 mmol, 1 eq) and azides (1.2 eq) were dissolved in a  
minimal amount of DMSO before loading into each well in proportions. The azides were 
added to the reaction in slight excess so as to ensure that all alkynes were consumed 
completely.4 Subsequently, 1 ml of a mixture of tBuOH/H2O (1:1 volume ratio) was 
applied to each well. The microplate was shaken for a few minutes, followed by 
sequential addition of catalytic amounts of sodium ascorbate (~10%) and CuSO4 (~1%) 
into each well to initiate the “Click Chemistry” assembly, which was continued at room 
temperature for another 8-12 hrs with shaking. The assembled products were used 
directly for subsequent LC-MS analysis and enzymatic assays without any further 
purification. LC-MS analysis of all 96 in situ-assembled products indicated the complete 
consumption of the alkynes and quantitative formation of the correct triazole products in 
almost every case. The LC-MS profiles of representative examples were shown below. 















































































































































































































































































































































































































5.7 Rapid Assembly of Metalloprotease Probes Using Click Chemistry 
 
































































Scheme 16 Synthesis route of Azide 32 
 
NHS ester (29):  
To a solution of 6-aminohexanoic acid 28 (7.87 g, 60 mmol) and NaOH (2 M, 50 
ml) in dioxane/water (2/1; 180 ml) at 0 °C was added (Boc)2O (15.7 g, 72 mmol). The 
reaction was allowed to proceed at room temperature overnight. Subsequently, dioxane 
was removed under reduced pressure and the resulting mixture was acidified to pH 2 with 
1 M HCl, followed by extraction with EA (3 x 80 ml). The combined organic layers were 
dried over Na2SO4, filtered and concentrated to furnish colorless oil, which was 
subsequently reacted with NHS (8.06 g, 70 mmol) and EDC (13.42 g, 70 mmol) in DMF 
at room temperature overnight. Upon column purification (20-40% EA/hexane), the 
desired product 29 was obtained as colorless oil (13.8 g, 42.0 mmol, 70%). 1H-NMR (300 
MHz, CDCl3) δ 4.60 (br s, 1H), 3.16 – 3.05 (m, 2H), 2.82 (s, 4H), 2.60 (t, J = 7.49 Hz, 
2H), 1.81 – 1.70 (m, 2H), 1.51 – 1.40 (m, 13H); ESI-MS: m/z [M+Na]+= 351.3.  
 
3-(4-benzoylphenyl)-2-(6-(tert-butoxycarbonyl)hexanamido)propanoic acid (30):  
29 (1.64 g, 5 mmol) dissolved in 15ml DMF was added H-p-Bz-Phe-OH (1.35 g, 
5 mmol) and DIEA (1.05 ml, 6 mmol). The reaction mixture was stirred under N2 
overnight. After that, DMF was removed in vacuo. The residue was taken into EA and 
washed with 1 M HCl. The EA layer was dried over Na2SO4, filtered and concentrated. 
Upon column chromatography (5-10% MeOH/DCM), the final product 30 was obtained 
as colorless oil (2.05 g, 4.25 mmol, 85%). 1H-NMR (300 MHz, CDCl3) δ 8.08 (s, 1H), 
7.74 – 7.66 (m, 4H), 7.63 – 7.56 (m, 1H), 7.49 – 7.44 (m, 2H), 7.31 – 7.26 (m, 2H), 4.83 
(br s, 1H), 3.41 – 2.96 (m, 2H), 2.21 – 2.05 (m, 2H), 1.61 – 1.47 (m, 2H), 1.47 – 1.32 (m, 
11H), 1.30 – 1.14 (m, 2H); ESI-MS: m/z [M-1]-
 
= 481.5.  
 
tert-butyl 2-aminoethylcarbamate (34):  
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A solution of di-tert-butyl dicarbonate (6.1 g, 28 mmol) in DCM (400 ml) was 
added dropwise over 6 h to a solution of ethylenediamine (11.2 ml, 166.7 mmol) 
predissolved in DCM (50 ml) while maintaining vigorous stirring. The reaction was 
continued with stirring for another 24 h at room temperature. Upon concentration, the 
resulting oil was taken into aqueous sodium carbonate (600 ml) and extracted with 
dichloromethane (2 x 300 ml). The organic layer was dried over anhydrous MgSO4 and 
concentrated under reduced pressure to yield 5 as colourless oil (4.47 g, 98%). 1H-NMR 
(300 MHz, CDCl3) δ 5.07 (br s, 1H), 3.17 – 3.06 (m, 2H), 2.74 (t, J = 5.91 Hz, 2H), 1.39 
(s, 9H); ESI-MS: m/z [M+1]+= 161.2.  
 
tert-butyl 2-azidoethylcarbamate (35): 
Sodium azide (2.25 g, 34.7 mmol) was dissolved in a mixture of H2O (5.7 ml) and 
CH2Cl2 (9.5 ml) at 0
oC. Triflyl anhydride (1.18 ml, 7.04 mmol) was subsequently added 
dropwise to the solution. The reaction was continued for 2 h. The CH2Cl2 layer was 
removed and the aqueous portion was extracted with CH2Cl2 (2 x 4.75 ml). The combined 
organic fractions, which contain triflyl azide, were washed once with saturated Na2CO3 and directly added to a solution containing 34 (564 mg, 3.52 mmol), K2CO3 (731 mg, 5.3 
mmol), CuSO4 pentahydrate (8.8 mg, 35.2 μmol), distilled H2O (11.4 ml) and CH3OH 
(22.7 ml). The resulting mixture was stirred at ambient temperature overnight. 
Subsequently, the organic solvents were removed under reduced pressure and the 
aqueous slurry was diluted with H2O (75 ml) and acidified to pH 2 with 6 N HCl. 
Following extraction with DCM (3 × 50 ml), the combined organic layers were washed 
with H2O, dried over MgSO4, and concentrated in vacuo. Upon column purification, the 
desired product 35 was isolated as colorless oil (590 mg, 3.17 mmol, 90%). 1H-NMR 
(300 MHz, CDCl3) δ 5.14 (br s, 1H), 3.22 – 3.11 (m, 2H), 2.79 (t, J = 5.91 Hz, 2H), 1.45 
(s, 9H); ESI-MS: m/z [M+1]+= 187.1.  
 
2-azidoethanamine (36):  
35 was deprotected by TFA/DCM as described above to give 36 (97% yield). 1H-
NMR (300 MHz, MeOD) δ 3.67 (t, J = 5.75 Hz, 2H), 3.07 (t, J = 5.58 Hz, 2H); ESI-MS: 




To compound 30 (1.93 g, 4 mmol) dissolved in DMF was added HBTU (1.90 g, 5 
mmol) and DIEA (0.87 ml, 5 mmol) at 0oC. The mixture was stirred for 10 min before 
addition of 36 (0.43 g, 5 mmol). The mixture was further agitated for another 12 h at 
room temperature, after which DMF was removed in vacuo and the residue was taken 
into ethyl acetate (50 ml). The organic layer was washed with saturated NaHCO3 (2 x 30 
ml), 1 M HCl (2 x 30ml), brine (2 x 30 ml), dried over anhydrous Na2SO4, and 
concentrated under reduced pressure to afford a yellow oily product. Purification of this 
compound by flash chromatography (silica gel, ethyl acetate/hexane = 3:1) furnished the 
intermediate as a white solid (1.65g, 3mmol, 75%). 1H-NMR (300 MHz, CDCl3) δ 7.81 – 
7.65 (m, 4H), 7.53 (t, J = 7.32 Hz, 1H), 7.41 (t, J = 7.50 Hz, 2H), 7.28 (m, 2H), 4.88 – 
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4.72 (m, 1H), 3.55 – 3.36 (m, 4H), 3.36 – 3.04 (m, 4H), 2.14 (t, J = 7.49 Hz, 2H), 1.62 – 
1.48 (m, 2H), 1.47 – 1.31 (m, 11H), 1.27 – 1.22 (m, 2H); ESI-MS: m/z [M+23]+= 573.4.  
Deprotection of above intermediate (1.65 g, 3 mmol) with TFA (10 eq) in DCM 
gave 31 as yellow oil (1.35 g, 3 mmol, ~100%). 1H-NMR (300 MHz, MeOD) δ 7.91 – 
7.75 (m, 4H), 7.66 (t, J = 7.32 Hz, 1H) 7.54 (t, J = 7.49 Hz, 2H), 7.44 (d, J = 8.37 Hz, 
2H), 4.73 – 4.68 (m, 1H), 3.41 – 3.31 (m, 4H), 3.28 – 3.21 (m, 1H), 3.04 – 2.97 (m, 1H), 
2.91 – 2.85 (m, 2H), 2.25 – 2.20 (m, 2H), 1.66 – 1.50 (m, 4H), 1.36 – 1.23 (m, 2H); ESI-
MS: m/z [M+1]+
 
= 451.4.  
 
Azide (32):  
Coupling of 31 with Rhodamine followed the same procedures as conversion 30 
to 31. Column purification (5%-10%-15% MeOH/DCM) was carried out to isolate the 
pure product (50% yield). 1H-NMR (300 MHz, MeOD) δ 8.60 – 8.42 (m, 1H), 8.26 – 
8.08 (m, 1H), 7.82 (s, 1H), 7.71 – 7.37 (m, 10H), 7.15 – 6.97 (m, 6H), 4.70 – 4.65 (m, 
1H), 3.78 – 3.61 (m, 8H), 3.35 – 3.32 (m, 2H), 3.31 – 3.19, (m, 1H), 2.99 – 2.89 (m, 1H), 
2.19 (t, J = 7.49 Hz, 2H), 1.63 – 1.46 (m, 4H), 1.39 – 1.20 (m, 14H); ESI-MS: m/z 
[M+1]+
 
= 920.2.  
 

































Second generation of MMP probeA-probeH
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Scheme 17 Construction of MMP probes library (A-H) using “Click Chemistry” 
 
 
Synthesis of the above 8 hydrophobic alkyne-containing warheads followed 
procedures similar to ones previously,
 
and details will be reported elsewhere. As shown 
in Figure 5.7.2, the alkyne (24 μmol, 1.2 eq) and the azide 32 (20 μmol, 1 eq) were 
dissolved in a minimal amount of DMSO. A mixture of tBuOH/H2O solution (1:1; 1 ml) 
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was subsequently added and the reaction was shaken for a few minutes to obtain a clear 
solution. The “click chemistry” was initiated by sequential addition of catalytic amounts 
of sodium ascorbate (0.1 eq) and CuSO4 (0.01 eq). The reaction was continued with 
shaking at room temperature for another 12 hrs. Upon further dilution with DMSO (1 ml), 
the reaction product was directly injected on LC-MS; results indicated the complete 
consumption of the azide and quantitative formation of the triazole final product in all 
cases. The final probes (probeA-probeH) were subsequently purified by semi-prep 
reverse phase HPLC and characterized by MS. Semi-prep HPLC conditions: 30% to 80% 
A in 60 min gradients.  
 
5.7.3 Synthesis of probes (I-L):  
The synthesis of probes (probeI-probeL) following scheme shown in Figure 
5.7.2 was problematic, due to the polar nature of the unprotected side chains which 
rendered the warheads difficult to purify before the “Click Chemistry” step. 
Consequently, the scheme below (Figure 5.7.3) was used to synthesize the probes instead. 
Briefly, warheads 6I-6L were converted to the corresponding alkynes, 6i-6l. 
Subsequently, “Click Chemistry” was carried out with the protected warheads, followed 
by direct TFA treatment to remove the protecting groups. Upon HPLC purification, the 
















































































Scheme 18 Construction of MMP probes library (I-L) using “Click Chemistry” 
 
 
General procedure for the coupling of 6I-6L with propargyl amine:  
 
To a solution of acid (6I to 6L) (5 mmol), HATU (6 mmol) and DIEA (6 mmol) in DMF 
(10 ml) was added propargyl amine (6 mmol) at room temperature under a nitrogen 
atmosphere. The mixture was stirred for 2-4 hrs. The solvent was removed in vacuo and 
the resulting oil residue was diluted with DCM and extracted with water. The combined 
DCM layers were dried over Na2SO4, filtered and concentrated. The crude product was 
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purified by column chromatography (80% DCM/hexane – 10% MeOH/DCM) to afford 






-(trityloxy)-2-(3-(trityloxy)propyl)succinamide (6i)  
Yield = 85%. 1H-NMR (300 MHz, MeOD) δ 7.42-7.27 (m, 30H), 3.99-3.78 (m, 
2H), 3.12-2.95 (m, 2H), 2.89 (s, 1H), 2.62-2.52 (m, 1H), 2.50-2.38 (m, 1H), 2.25-2.10 (m, 
1H), 1.50-1.21 (m, 4H); ESI-MS: m/z [M+23]+= 736.1.  
 
tert-butyl 7-oxo-5-(prop-2-ynylcarbamoyl)-7-(trityloxyamino) heptylcarbamate (6j)  
Yield = 80%. 1H-NMR (300 MHz, MeOD) δ 7.46-7.33 (m, 15H), 4.00-3.75 (m, 
2H), 3.09-2.92 (m, 2H), 2.62-2.58 (m, 1H), 2.52-2.45 (m, 1H), 2.25-2.11 (m, 1H), 2.09-
2.02 (m, 1H), 1.50 (s, 9H), 1.48-1.25 (m, 4H), 1.25-1.15 (m, 4H); ESI-MS: m/z [M+23]+
 
= 606.3.  
 
tert-butyl 5-oxo-3-(prop-2-ynylcarbamoyl)-5-(trityloxyamino) pentanoate (6k)  
Yield = 90%. 1H-NMR (300 MHz, MeOD) δ 7.43-7.26 (m, 15H), 3.99-3.57 (m, 
4H), 2.80 (s, 1H), 2.48-2.32 (m, 1H), 2.30-2.15 (m, 2H), 1.42 (s, 9H); ESI-MS: m/z 






-(trityloxy)succinamide (6l)  
Yield = 75%. 1H-NMR (300 MHz, MeOD) δ 7.42-7.22 (m, 19H), 4.04-3.62 (m, 
4H), 3.05 (s, 3H), 2.35-2.22 (m, 1H), 2.18 (s, 1H), 2.12-1.90 (m, 2H); ESI-MS: m/z 
[M+23]+= 605.2.  
 
“Click Chemistry” followed by TFA deprotection  
 
The alkyne 6i-6l (24 μmol, 1.2 eq) and the azide 32 (20 μmol, 1 eq) were 
dissolved in a minimal amount of DMSO. A mixture of tBuOH/H2O solution (1:1; 1 ml) 
was subsequently added and the reaction was shaken for a few minutes to obtain a clear 
solution. The “click chemistry” was initiated by sequential addition of catalytic amounts 
of sodium ascorbate (0.1 eq) and CuSO4 (0.01 eq). The reaction was continued with 
shaking at room temperature for another 12 hrs. Upon further dilution with DMSO (1 ml), 
the reaction product was directly injected on LC-MS; results indicated the complete 
consumption of the azide and quantitative formation of the triazole final product in all 
cases. Subsequently, TFA (4 ml) and TIS (200 μl) were added to the reaction mixtures. 
The mixture was stirred for 1 hr, following which the solvent was removed in vacuo. The 
crude product was directly purified by semi-prep RP-HPLC (conditions: 30% to 100% A 
in 60 min).  
 
5.7.4. LC-MS characterization of the final probes (A-L):  
Due to the presence of two isomeric forms of the Rhodamine dye used (e.g. 5-and 
6-Tetraethylrhodamine) in the synthesis, both isomers of all 12 final probes were 
produced as a result (Figure 20). They were unambiguously confirmed by LC-MS 
profiles which indicate, in every final probe, two peaks with equal intensity and identical 
molecular weight, but differing slightly in the retention time, were produced. We were 






















5- or 6- isomer
 
 
Figure 21 Two isomers of the second generation MMP probes 
ProbeA:  
 
LC conditions: 30%-80% A in 20 min  
 





















































ESI-MS: [M+1]+ = 1146.6
 















ESI-MS: [M+1]+ = 1146.6
 












ESI-MS: [M+1]+ = 1146.6
 































ESI-MS: [M+1]+ = 1179
 
















ESI-MS: [M+1]+ = 1207
 
















ESI-MS: [M+1]+ = 1207
 

































ESI-MS: [M+1]+ = 1172
 































ESI-MS: [M+1]+ = 1172.6
 
















ESI-MS: [M+1]+ = 1224
 













ESI-MS: [M+1]+ = 1224











LC conditions: 30%-100% A in 20 min  
P1'=
Isomer 2









ESI-MS: [M+1]+ = 1148
OH Isomer 1




LC conditions: 30%-100% A in 20 min  
 




















































ESI-MS: [M+1]+ = 1148
OH
 







































ESI-MS: [M+1]+ = 1260
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